


REVIEW

Open Access



Curcuma Longa (turmeric): from traditional applications to modern plant medicine research hotspots

Wei-Wei Tian^{1,2}, Li Liu¹, Ping Chen², Dong-Mei Yu¹, Qing-Miao Li², Hua Hua^{1*}  and Jun-Ning Zhao^{1,3*}

Abstract

Turmeric, derived from the dried rhizome of *Curcuma longa* L., receives widespread attention because of its applications in pharmaceutical, food, cosmetic and other industries. Traditionally, it has been widely used in Ayurveda medicine and traditional Asian medicine such as traditional Chinese medicine, for treatment of digestive, respiratory and circulatory diseases, as well as skin diseases. However, a comprehensive review of traditional applications, modern clinical applications, and related products remains largely unexplored. Here, we conduct a systematic summary of its pharmacological activities, including anti-inflammatory activity, anti-oxidant activity, anti-diabetic activity, anti-tumor activity, neuroprotective activity, hepatoprotective activity, anti-microbial activity and others. Additionally, we explore the randomized controlled trials, guiding future preventive healthcare strategies and clinical practices. Furthermore, we also discuss the turmeric-related products, involving medicines, health foods, herbal dietary supplements, and cosmetics, offering novel insights into relevant product development. Totally, this review provides a comprehensive understanding of turmeric on botany, history and traditional applications, pharmacological activities, clinical applications, and related products. Finally, based on the generalized science of Chinese material medica and advanced front technologies, the future research opportunities of turmeric are briefly explored.

Keywords *Curcuma longa* L., Traditional applications, Pharmacological activities, Clinical applications, Products

Introduction

The genus *Curcuma*, composed of roughly 130 species, is widely distributed in tropical and subtropical areas, including China, India, Thailand, Malaysia, Indonesia, etc. [1]. Some *Curcuma* species possess medicinal, edible, and ornamental values. *Curcuma longa*, the most well-known species of the *Curcuma* genus, is grown in warm climates and cultivated in tropical and subtropical regions worldwide. It is known by multiple names across cultures such as turmeric in English, Haldi in Hindi, manjal in Tamil, kunyit in Indonesian, Jianghuang in Chinese, and Kyoo in Japanese. The medicinal history of turmeric dates back 4 000 years [2]. Turmeric has historically been used as a traditional herbal medicine in China, India, Thailand, Malaysia, Indonesia, Japan, South Korea, and other countries. Traditionally, turmeric has been utilized

*Correspondence:

Hua Hua
hrhr2014@163.com
Jun-Ning Zhao
zarmy@189.cn

¹ Key Lab.: Biological Evaluation of TCM Quality of the State Administration of Traditional Chinese Medicine, Sichuan Engineering Technology Research Center of Genuine Regional Drug, Sichuan Provincial Engineering Research Center of Formation Principle and Quality Evaluation of Genuine Medicinal Materials, Translational Chinese Medicine Key Laboratory of Sichuan Province, Sichuan Institute for Translational Chinese Medicine, Chengdu 610041, China
² Sichuan Academy of Chinese Medical Sciences, Chengdu 610041, China
³ National Center for Nanoscience and Technology, Beijing 100190, China



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

for treatment of respiratory, digestive, and circulatory diseases, as well as skin diseases.

Nowadays, extensive research has confirmed that turmeric contains a variety of active ingredients, such as diphenylalkanooids, terpenoids, aromatics, steroids, fatty acids, minerals, and nucleosides. These components contribute to the treatment of inflammatory diseases, digestive diseases, cardiovascular diseases, skin diseases, cancers, etc. As traditional herbal medicine, medicinal and food homologous variety, and cosmetic ingredient, turmeric is widely used in pharmaceutical, food, cosmetic and other industries, making products such as drugs, health foods, food additives, dietary supplements, cosmetics. Representing the largest application segment, the pharmaceutical industry accounts for over 50% of the worldwide market [3]. As the main active ingredient of turmeric, curcumin market size (pharmaceutical, food and cosmetics) reached \$98.7 million in 2023 and is estimated with a 9.1% compound annual growth rate by 2032. Recent advancements in curcumin extraction techniques, including high-intensity and ultrasonic-assisted water filtration, have improved both the yield and purity of curcumin, resulting in higher potency and efficacy. Novel delivery systems such as liposomes, micelles and nanoparticles significantly increase curcumin absorption and boost its therapeutic efficacy. The expanding use in diverse industries, including pharmaceutical industry, food industry, and cosmetic industry, is also contributing to the product uptake (<https://www.gminsights.com/>). Therefore, this review aims to encompass various applications of turmeric, including its history and traditional applications, clinical applications, and related products.

Finally, based on the generalized science of Chinese material medica, the cultivation system of large variety of turmeric and the application system of the large health industry are constructed.

Botany

Curcuma longa, a triploid specie ($2n=3x=63$), belongs to the genus *Curcuma*. Morphologically, turmeric is a perennial herb that reaches a height of approximately 1–1.5 m. The leaves are basal, usually oblong to elliptic in morphology, 30–50 cm in length and 15–18 cm in width, with dark green on the upper surface and pale green beneath. The sterile flowers present pale yellow petals with a purplish covering, complemented by green bracts with a purplish colour. The rhizomes (underground stem) are well-developed, clustered, with many branches, oval or cylindrical, orange or yellow, balmy smell and bitter taste (Fig. 1). There are many varieties, including Suguna, Sudarsana (tolerant to rhizome rot), Suroma, IISR Alleppey Supreme (resistant to leaf blotch), IISR Prabha, IISR Prathiba (high yielding variety), Co.1, BSR.1 (resistant to drought), BSR.2, Rashmi (bold rhizomes), Chuanjianghuang 1 (high productivity and adaptability variety), etc. [4]. Pheap et al. reported five *Curcuma longa* varieties collected from Siem Reap province, Cambodia, including Black ginger (BG), Broteal lakai (BLK), Broteal roneang (BRN), Sena 100 (SN1) and Fire ginger (FG). The results showed that curcumin was the main component in BG, BRN and SN1, while not detected in FG and BLK [5]. Alam et al. evaluated the rhizome yield and related traits of 53 *Curcuma longa* genotypes from 2019 to




Fig. 1 Botanical characteristics of turmeric. **A** global distribution of turmeric (www.gbif.org), **B, C** turmeric, **D** the flowers of turmeric, **E, F, G** the rhizomes of turmeric, **H** a brief summary of botanical characteristics of turmeric

2021. According to the yield and overall ranking, the top ten genotypes were identified as superior, such as T0129, T0121, T0117, T0106, T0103, T0094, T0085, T0082, T0061, and T0015 [6]. Yin et al. successfully constructed a high-quality genome assembly of *Curcuma longa* spanning 1.11 Gb, which provided insight into germplasm resources identification, new varieties breeding, and disease-resistant gene mining [7].

Data from the GBIF database (<https://www.gbif.org/>) shows that the resources of turmeric on a global scale are mainly distributed in India, China, Thailand, Singapore, Philippines, Malaysia, Indonesia, Australia, and other countries (Fig. 1). India contributes 80% of the global turmeric production [8], while China accounts for 8%, Myanmar 4%, and Nigeria and Bangladesh 3% each. Gururani et al. assessed the differences in chemical profiles and biological activities of essential oil derived from native *Curcuma longa* rhizome cultivars in Garhwal and Kumaun regions of Uttarakhand, India. The findings revealed that the quantity and composition of essential oil derived from turmeric rhizomes harvested in Garhwal and Kumaun regions of Uttarakhand exhibited variations [9]. In China, turmeric is widely cultivated in Sichuan, Yunnan, Fujian, Guangdong, Taiwan, and other provinces. Qianwei county in Sichuan province is the main producing areas of turmeric, accounting for about 60% of national output and called “Chuan Jiang Huang”. We constructed the bioinformatics database and production layout visual analysis platform of medicinal plants, covering geographic data, phenotype data, compound

data, and genetic data of turmeric in Sichuan province [10].

History and traditional applications

Turmeric has been utilized by humans for nearly 6,000 years [11]. Historically, turmeric was widely used in Ayurveda medicine and traditional Asian medicine such as traditional Chinese medicine. The exact origin of turmeric are unknown. According to records, the use of turmeric in India dated back roughly 6,000 years. It probably spread to both Morocco and China by around 700 AD, reached East Africa by 800 AD and West Africa by 1200 AD. Then in the thirteenth century, Arab merchants brought turmeric to Europe [12]. Alternatively in sixteenth century, turmeric entered Turkish cuisine, where it served as a natural coloring agent to give yellow color to the saffron-infused rice dessert [13]. Until eighteenth century, turmeric was introduced to Jamaica. Nowadays, turmeric has been widely spread around the world, and used as drugs, health foods, food additives, dietary supplements, cosmetics (Fig. 2).

Traditional applications in India

Owing to its bright yellow color, turmeric is referred to “Indian saffron” “manjal” “haldi”. Traditionally in India, turmeric was used as drugs, religious ceremonies, dyes, cosmetics, spices, and seasonings. The medicinal use of turmeric was first documented in ‘Atharveda’. In the Ayurveda system, turmeric has been applied to cure common cold, stomachache, flatulence, indigestion, hepatic disorders, jaundice, bilious attack, gallstones,




Fig. 2 The history and traditional applications of turmeric

rheumatism, irregular menstruation, dermatological disorders (skin infections, pimples and foul ulcers), external injuries (sprains, wounds, swellings and cuts), inflammatory diseases (rhinitis, arthritis and inflammatory bowel disease) [14, 15]. Moreover, turmeric was used in many important ceremonies, such as weddings. Additionally, turmeric was employed to religious observances, including Hinduism and Buddhism. In Hinduism and Buddhism, turmeric powder symbolized fertility, prosperity, and purity. Further, the conventional saffron-colored robes donned by Buddhist monks was dyed with turmeric. Likewise, turmeric was traditionally used as a facial mask to enhance the complexion and reduce skin blemishes. Also known as the “Spice of life”, turmeric has been utilized for spice and food seasoning, adding flavor and color to dishes.

Traditional applications in China

After introduced into China in the Tang Dynasty, turmeric immediately attracted widespread attention. The medicinal use of turmeric was first mentioned in ‘*New Revised of Materia Medica*’ (659 AD). Subsequently, turmeric has been recorded in numerous classical ancient Chinese medicine books, such as ‘*Ri Hua-zi’s Materia Medica*’, ‘*Bencao Tujing*’, ‘*Compendium of Materia Medica*’, providing detailed information on the medicinal effects of turmeric. Traditional Chinese medicine (TCM) is mainly divided into two categories, traditional Chinese medicinal material, and traditional Chinese medicine preparation [16]. Turmeric is used as traditional Chinese medicinal material, and traditional Chinese medicine preparation. Based on the ‘*Catalogue of Ancient Classical Formulas (First Batch)*’ and ‘*Catalogue of Ancient Classical Formulas (Two Batch)*’, turmeric is widely used in TCM and minority medicine, including Tibetan medicine, Mongolian medicine, and Dai medicine (Table 1). In TCM practice, the rhizomatous and tuberous parts of *Curcuma longa* are classified as two distinct herbal medicines (named as “Jiang Huang” and “Huang Si Yu Jin”, respectively). The “Jiang Huang” is generally believed to be warm and suitable for treating chest and hypochondriac pain, menstrual pain, amenorrhea, postpartum abdominal pain, rheumatic arthralgia, traumatic injury, jaundice, etc. But the “Huang Si Yu Jin” is characterized by its cold properties and is associated with the liver, heart, and lung meridians. It is used for promoting the circulation of qi and blood, relieving pain, clearing heat and cooling the blood, as well as for its cholagogic (bile-promoting) and jaundice-alleviating effects.

Traditional applications in other countries

Also, in South Asia, turmeric has been used for treatment of cuts, burns, and bruises [17]. In Japan, turmeric has been widely used for digestive disorders, and enjoyed as a tea, particularly in Okinawa [18]. In Korea, the turmeric was used as antidotes for hematuria and anxiety [19]. The ancient Hawaiians used turmeric for treatment of sinus infections, ear infections and gastrointestinal ulcers [2]. In Nigeria, turmeric was utilized as spices and herbs (for joint pain and inflammation) [20]. In Islamic medicine, powdered *Curcuma longa* extract was used to curing pimples and wounds [21]. Additionally, in Kurdistan and surrounding areas, *Curcuma longa* has been utilized in relieving joint inflammation, promoting weight management, enhancing culinary flavor, as well as exhibiting antiviral and anticancer applications [22]. Moreover, *Curcuma longa* has been used for treatment of the diseases related to blood and circulatory system, digestive system, musculoskeletal system, urinary system, etc.

Applications in modern medical practice

Phytochemical composition

Recently, numerous bioactive compounds have been identified through diverse analytical techniques, such as HPLC (high-performance liquid chromatography), GC–MS (gas chromatography mass spectrometry), LC–MS (liquid chromatography mass spectrometry), and NMR (nuclear magnetic resonance). Turmeric contains a variety of active pharmaceutical ingredient, including diphenylalkanooids, terpenoids, aromatics, steroids, and fatty acids. Additionally, turmeric also contains a variety of macro and micro elements, including K, Mg, Ca, Na, Al, Cr, Cu, Mn, Rb, Sr, and Zn [23]. Recent years, various reports revealed that microRNAs (miRNAs) could be the potential active ingredients and critical material foundation of traditional Chinese medicine, which have been proved to transfer across species, facilitating cross-kingdom regulation by incorporating themselves into specific target gene-driven regulatory pathways, thereby executing associated biological functions [24]. Our previous study suggested that turmeric extract contained abundant miRNAs, including 10 known and 115 novel miRNAs, predicting 13,575 target genes.

The pharmacological activities

Modern pharmacological studies showed that turmeric have many activities, including anti-inflammatory activity, anti-oxidant activity, anti-diabetic activity, anti-tumor activity, neuroprotective activity, hepatoprotective

Table 1 Catalogue of ancient classical formulas containing turmeric

| Rank | Prescription name | Prescription source | Prescription compositions | Action of prescription |
|------|------------------------|-----------------------|---|--|
| 1 | Huanglian Gao | Yizongjinjian | <i>Coptis chinensis</i> , <i>Angelica sinensis</i> , <i>Rehmannia glutinosa</i> , <i>Phellodendron chinense</i> , <i>Curcuma longa</i> | Treat retention of heat-phlegm in the lung, xerostomia, edema and pain, eczema, erythema and swelling, thermal ulceration, burns and scalds, and mammary fissures |
| 2 | Wuwei Jianghuang Pill | Xiuduoyixuehuiji | <i>Curcuma longa</i> , <i>Phyllanthus emblica</i> , <i>Berberis amurensis</i> , <i>Thlaspi arvense</i> , <i>Tribulus terrestris</i> | Treat lumbocrural pain, turbid urine, rectal tenesmus, urinary frequency, urinary urgency caused by 'Jingnisaku' and 'Kaichang' |
| 3 | Shiwei Qinglan San | Sibuyidian | <i>Dracocephalum tanguticum</i> , <i>Taraxacum mongolicum</i> , <i>Ribes emodens</i> , <i>Hippophae rhamnoides</i> , <i>Curcuma longa</i> , <i>Rhododendron primuliflorum</i> , <i>Cinnamomum cassia</i> , <i>Myristica fragrans</i> , <i>Polygonatum sibiricum</i> , <i>Tinospora sinensis</i> | Treat abdominal distension and pain, gastroesophageal reflux, eructation, abdominal distension, abdominal pain, constipation, and hemotheczia caused by 'Peigenmubu' |
| 4 | Pipaye erwei Decoction | Tongwagajide | <i>Eriobotrya japonica</i> , <i>Curcuma longa</i> | Treat menorrhagia, excessive vaginal discharge and generalized weakness |
| 5 | Yapengle | Danghayadaoxiangnen | <i>Curcuma longa</i> , <i>Zingiber montanum</i> , <i>Acorus calamus</i> , <i>Rheum franzenbachii</i> , <i>Artemisia argyi</i> | Treat gastralgia, epigastric distending pain, vomiting, and diarrhea |
| 6 | Yajiezhanla | Danghayalong | <i>Curcuma longa</i> , <i>Zingiber montanum</i> , <i>Nigella glandulifera</i> , <i>Zingiber officinale</i> | Treat stroke, deafness, cardiac and chest pain, hematuria, urolithiasis, sallow complexion and emaciation, abdominal distension and pain |
| 7 | Yalongjiuduanga | Danghayahemai | <i>Curcuma longa</i> , <i>Zingiber montanum</i> , <i>Acorus calamus</i> , <i>Foeniculum vulgare</i> , <i>Amonum kravanh</i> , <i>Camphora officinarum</i> , <i>Piper nigrum</i> , <i>Ferula sinkiangensis</i> | Treat abdominal distension and pain, nausea and vomiting, dysmenorrhea, and muscle and joint crampy pain |
| 8 | Yajieduan | Danghayamengdai | <i>Curcuma longa</i> , <i>Zingiber montanum</i> , <i>Acorus calamus</i> , <i>Artemisia argyi</i> , <i>Stephania cepharantha Hayata</i> , <i>Eclipta prostrata</i> , <i>Curcuma zedoaria</i> | Treat indigestion, abdominal distension and pain, belching and acid reflux, peptic ulcer, and gastric spasm |
| 9 | Yawalutazhuan | Danghayadaoxiangnen | <i>Nigella glandulifera</i> , <i>Curcuma longa</i> , <i>Zingiber montanum</i> , <i>Piper nigrum</i> | Used for the treatment of rheumatism-related myalgia, epigastric and abdominal pain, and dizziness and headache |
| 10 | Shengjiang San | Shanghanwenyitiaobian | <i>Bombax mori</i> , <i>Cryptotympana pustulata</i> , <i>Curcuma longa</i> , <i>Rheum officinale</i> | – |




Fig. 3 The pharmacological activities of turmeric

activity, anti-microbial activity and others. The pharmacological activities were summarized in Fig. 3.

Anti-inflammatory activity

Generally, turmeric is recognized for exhibiting various biological activities, with anti-inflammatory activity being one of the most notable characteristics. Over the years, numerous studies confirmed that turmeric effectively inhibits multiple signaling pathways in inflammation including mTOR/PI3K/Akt, TLR4/NF-κB, MAPKs, NLRP3, and JAKs/STATs. For example, Dai et al. demonstrated that curcumin significantly ameliorated collagen-induced arthritis rat model in vivo by inhibiting the increased levels of key pro-inflammatory mediators such as TNF-α, IL-1β, MMP-1, and MMP-3 via the mTOR pathway [25]. The protective effect of curcumin against high glucose-induced inflammation in retinal pigment epithelial cells was achieved through suppression of the ROS/PI3K/AKT/mTOR pathway [26].

The transcription factor NF-κB, as a central regulator of inflammatory responses, plays a crucial role in the pathogenesis of diverse inflammatory disorders. Therefore, the NF-κB pathway provides a good choice for treatment of inflammatory diseases. In BV2 cells, curcumin suppressed LPS-induced neuroinflammation by enhancing microglial M2 polarization through mechanisms involving the TREM2/TLR4/NF-κB signaling pathways. In monosodium iodoacetate (MIA)-induced osteoarthritis rat model, curcumin possessed an anti-inflammatory

effect against osteoarthritis and prevented knee damage via blocking the TLR4/NF-κB signaling pathway [27]. Furthermore, curcumin-loaded polysaccharide microparticles mitigated DSS-induced ulcerative colitis through modulation of gut microbiota and the MAPK/NF-κB/Nrf2/NLRP3 signaling axis [28].

Moreover, the essential oils extracted from the rhizome of turmeric also have anti-inflammatory activity. α-turmerone, *ar*-turmerone, and β-turmerone were the main components in essential oils, accounting for 12.9%, 42.6%, and 16.0%, respectively [29]. *ar*-Turmerone, a turmeric oil derived from turmeric, exhibited anti-inflammatory activity against Hela-STAT3-Luc cells. It possessed an inhibitory effect by activating the NF-κB and STAT3 pathways, with respective IC₅₀ values of 22.7 ± 3.2 μM and 14.21 ± 4.7 μM. Further evaluation of the anti-inflammatory activity of turmeric showed that α-turmerone attenuated HIF-1α-mediated signaling by suppressing desferrioxamine-induced activation of erythropoietin promoter activity [30]. Additionally, in activated microglial cells, the inhibition of the IKK/NF-κB signaling pathway by turmeronol A and turmeronol B could potentially block the generation of inflammatory mediators [31]. 3-hydroxy-1,7-bis(4-hydroxy-phenyl)-1,3-heptadiene-5-one and bisabola-3,10-diene-2-one, also displayed anti-inflammatory activities against LPS-induced NO production in RAW264.7 cells. Both of them showed the IC₅₀ values of 14.42 and 12.93 μM, respectively, compared to the positive control hydrocortisone

with IC_{50} values of 37.64 μ M [32]. Calebin A, a bioactive compound derived from turmeric, prevented stress-induced damage in chondrocytes by suppressing programmed cell death, extracellular matrix breakdown, and key pathways involved in inflammatory responses (NF- κ B, MMP9) or inhibition of autophagy (mTOR/PI3K/Akt) [33].

Anti-oxidant activity

Turmeric has potential anti-oxidant activity by inhibiting reactive oxygen species (ROS) accumulation, activating antioxidant signaling pathways, and inducing oxidative damage. One study suggested that curcumin can scavenge or neutralize ROS through its phenolic OH and the β -diketone moiety [34]. A previously reported study showed that curcumin could prevent the release of mitochondrial type 1 hexokinase, a key enzyme controlling brain glucose metabolism, and induce an increase in ROS through α -synuclein fibrillation products [35]. Additionally, curcumin exerted hepatoprotective property against LPS-induced acute and chronic hepatic toxicity under stress conditions, mediated by suppressing reactive oxygen species accumulation, restoring normal endoplasmic reticulum protein folding functionality, and alleviating hepatic dyslipidemia [36]. As a key transcription factor, Nrf2 regulates the expression of numerous antioxidant genes. One study showed that curcumin enhanced the oxidative stress resistance in corneal endothelial cells by activating the Keap1/Nrf2/ARE signaling pathway [37]. Another study found that curcumin prevented cadmium or H_2O_2 -induced oxidative stress via Nrf2/ARE signaling and autophagy in myeloid cells [38]. Another study also demonstrated that curcumin displayed renoprotection activity via activating the nuclear levels of Nrf2, reducing the nuclear activity of NF- κ B, suppressing NADPH oxidase, and down-regulating PKC β II/p [66] Shc axis [39]. Besides, in SH-SY5Y cells, curcumin reduced oxidative damage caused by OGD/R through modulation of the miR-1287-5p/LONP2 pathway [40]. In the oxidative damage rat models caused by sodium arsenate, curcumin enhanced the antioxidant defense system by increasing the enzymatic activities of CAT, GR, GPx, and SOD [41].

The ethanol extract of turmeric showed scavenging activities against HO, 2,2-diphenyl-1-picrylhydrazyl (DPPH), and 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS) [42]. The essential oil extracted from turmeric rhizomes demonstrated concentration-dependent antioxidant activity against ABTS and DPPH radicals, with respective IC_{50} values of 0.54 mg/mL and 10.03 mg/mL [43]. In vivo mouse models of myocardial infarction, by regulating Nrf2-SIRT3 pathway, tetrahydrocurcumin alleviated oxidative stress as well as mitochondrial damage [44]. Furthermore, the 1:1 mixture of

dimethylmethoxy chromanol and turmeric root extract reduced ultraviolet-induced oxidative damage in HaCaT cells via cooperative enhancement of cellular antioxidant enzyme systems [45].

Anti-diabetic activity

Diabetes impacted 529 million individuals globally in 2021, with estimates projecting this number will surge to 1.31 billion by 2050 [46]. Turmeric exhibits potent anti-diabetic activity via suppressing oxidative stress and inflammatory process [47]. Three curcuminoids, including curcumin, demethoxycurcumin, and bisdemethoxycurcumin, significantly reduced blood glucose, alanine aminotransferase, and aspartate aminotransferase levels, and improved liver histopathology score, indicating that these three curcuminoids have potent anti-diabetic efficacy [48]. Zhong et al. ameliorated insulin resistance, glucose intolerance, triglyceride accumulation, and pyruvate intolerance in the liver of mice on a high-fat diet by modulating gut microbiota [49]. In addition, curcumin supplementation enhanced the hepatic expression of insulin-degrading enzyme and maintained the structural integrity of pancreatic islets [50]. It has been demonstrated that 15 μ M of curcumin could induce preadipocyte apoptosis and inhibit adipocyte differentiation. This mechanism is associated with the down-regulation of PPAR γ and CCAAT enhancer binding proteins, the prevention of differentiation medium-induced down-regulation of β -catenin, and a reduction lipid accumulation in 3T3-L1 adipocytes [51]. Two other studies proved that curcumin regulated lipid metabolism and suppressed chronic inflammation by targeting white adipose tissue, playing a key role in addressing obesity-related health issues [52, 53]. Additionally, in a high-fat diet-induced obesity mouse model, dietary intervention with curcumin demonstrated an ability to alleviate metabolic disease in vivo. This effect was mediated by the prevention of uncoupling protein 1 expression in brown adipose tissue and the modulation of macrophage functional polarity in white adipose tissue [54].

Anti-tumor activity

Recently, turmeric has gained considerable attention due to its notable anti-tumor activity. Many studies have demonstrated that curcumin is the main anti-tumor active ingredient derived from turmeric. It exhibits significant anti-tumor activity in treating multiple cancers, such as breast cancer, cervical cancer, colorectal cancer, lung cancer, papillary thyroid cancer, etc. Jin et al. found that curcumin suppressed cell proliferation and induced apoptosis in vitro, with the underlying mechanism involving the activation of miR-192-5p and inhibition of the PI3K/Akt pathway [55]. Additionally, in

B-CPAP cells, curcumin promoted apoptosis and suppressed proliferation by inhibiting lncRNA LINC00691, potentially via modulation of the Akt signaling pathway [56]. In addition, in colorectal cancer cells, curcumin inhibited colorectal cancer metastasis by activation of the ROS/KEAP1/NRF2/miR-34a/b/c pathway. Moreover, the therapeutic efficacy of 5-FU against p53- and miR-34a/b/c-deficient colorectal cancer cells may be potentiated by curcumin [57]. Another study demonstrated that curcumin suppressed the proliferation, metastasis, epithelial mesenchymal transition, and stem cell-like properties in triple-negative breast cancer through modulation of the Hedgehog/Gli1 signaling cascade [58]. Angiogenesis is one of the important mechanisms of the occurrence, development, invasion, and metastasis of tumors. Jin et al. indicated that the combination of curcumin and (-)-epigallocatechin-3-gallate inhibited angiogenesis triggered by the colorectal cancer microenvironment through modulation of the JAK/STAT3/IL-8 signaling axis [59]. Moreover, curcumin suppressed angiogenesis through downregulation of vascular endothelial growth factor expression. Zhang et al. demonstrated that combined use of curcumin and homoharringtonine may suppress lymphoma cell growth and blood vessel formation by targeting the VEGF/Akt signaling pathway [60].

Curzerene, a prominent sesquiterpene in *Curcuma* rhizomes, exhibits notable anti-tumor effect in both cellular and animal models. In vitro studies revealed that curzerene exhibited antiproliferative effects with an IC_{50} value of 47.0 μ M over 72 h, causing G2/M phase cell cycle arrest and triggering programmed cell death in SPC-A1 human lung adenocarcinoma cells. Additionally, in vivo experiments showed significantly inhibition of tumor growth in SPC-A1 cell-bearing nude mice treated with curzerene at the dosage of 135 mg/kg/day. The mechanism of anti-tumor activity could be related to the induction of down-regulation of GSTA1 protein and mRNA expression [61]. Demethoxycurcumin, a curcumin derivative, also anti-tumor activity in diverse human cancer cell lines. Kao et al. proved that demethoxycurcumin suppressed cervical cancer progression by modulating PPAR γ -mediated pathways, influencing both cellular proliferation and apoptotic processes [62]. Another study suggested that DMC-BH inhibited orthotopic glioma stem cell proliferation via targeting JNK/ERK axis [63]. The above evidence indicated that turmeric and its active components exerted anti-tumor activity mainly through modulation of tumor proliferation, tumor invasion and metastasis, tumor angiogenesis, etc. The mechanisms were involved in targeting PI3K/Akt, JAK/STAT3, Hedgehog/Gli1, PPAR γ , JNK/ERK signaling pathways.

Neuroprotective activity

A β (amyloid-beta) is a protein that accumulates in the brain and forms plaques, which is a hallmark feature of Alzheimer's disease (AD). The accumulation of A β plaques is deemed to disrupt cell function and trigger neuroinflammation, leading to cognitive decline and memory loss characteristic of AD. Four curcuminoids derived from turmeric, curcumin, demethoxycurcumin, bisdemethoxycurcumin and (E)-1,7-bis-(4-hydroxyphenyl)-1-hepten-3,5-dione—were found to protect PC12 cells from A β insult (ED_{50} : 0.5–10 μ g/mL), compared to the positive control (ED_{50} : 37–39 μ g/mL). Feng et al. found that the curcumin nanoparticles inhibited A β aggregation and promoted A β phagocytosis/clearance in microglia. Subsequently, curcumin nanoparticles were endocytosed by microglia and inhibited TLR4/NF- κ B pathway for microglia polarization [64]. One study confirmed that the neuroprotective potential of turmeric extract may be mediated by decreasing the levels of malondialdehyde in plasma and brain, and increasing the enzyme activities of SOD, CAT, and GPx in the brain [65]. Then, another study proved that administration of curcumin (50 mg/kg) in a 6-hydroxydopamine-induced parkinson's disease rat model significantly reduced the aggregation of α -synuclein and improved the parkinsonian disability scores [66]. Besides, intermedin B, isolated and identified as an active compound from turmeric, exhibited neuroprotective effects against HT22 hippocampal cells by reducing inflammation and reactive oxygen species generation [67]. The above studies showed that turmeric demonstrates significant neuroprotective properties by inhibited A β aggregation and the generation of ROS, and modulating inflammatory pathways.

Hepatoprotective activity

Additionally, turmeric is well-recognized for its hepatoprotective activity. It was demonstrated that the protective effect of curcumin against liver oxidative injury involves restoring gut microbiota balance and lipid metabolism dysregulation caused by Ochratoxin A [68]. Cunningham et al. suggested that curcumin supplementation demonstrated efficacy in decreasing hepatocellular inflammation, hepatic steatosis, NAFLD activity scores, and serum biomarkers associated with liver injury. Totally, in female wistar rat models, curcumin administration improved NASH phenotype, with significant mitigation of hepatocellular inflammation [69]. Furthermore, curcumin supplementation showed the protective effect of hepatic steatosis induced by bisphenol A. The mechanism could potentially regulate gut microbiota homeostasis while reinforcing intestinal barrier integrity, consequently

reducing liver inflammatory response triggered by lipopolysaccharide [70]. Formulating curcumin into nanoparticles or liposomes represents a viable strategy to circumvent its inherent bioavailability limitations. Hussain et al. reported that curcumin-incorporated nano-lipid carrier demonstrated hepatoprotective effect in rats with cypermethrin-induced hepatotoxicity [71]. When compared with curcumin, nanoengineered curcumin exhibited enhanced antioxidant capacity and hepatoprotective effect [72].

Anti-microbial activity

Curcuma longa, known for its anti-microbial activity, showed anti-bacterial activity against *Bacillus subtilis*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Vibrio cholerae*, exhibiting MIC values within the range of 125–1000 µg/mL [73]. Also, at 1000 mg/L, the hexane extract of *Curcuma longa* exhibited anti-fungal effect against *Phytophthora infestans*, *Rhizoctonia solani*, and *Erysiphe graminis*, while the ethyl acetate extract of *Curcuma longa* demonstrated fungicidal property against *Botrytis cinerea*, *Puccinia recondita*, *Phytophthora infestans*, and *Rhizoctonia solani* [74]. Additionally, Vetvicka et al. found that five curcumin samples purchased from Sabinsa, Sigma, and Jarrow Formulas showed some anti-*Helicobacter pylori* effects [75]. Lobo de Sá et al. suggested the inhibitory growth activity of curcumin on *Campylobacter jejuni* [76]. Martins et al. reported anti-bacterial activity of curcumin against *Paracoccidioides brasiliensis*. Curcumin significantly reduced the attachment capability of candida species to human buccal epithelial cells [77]. Moreover, *Curcuma longa* also showed anti-viral activity. Curcumin at 40 µM suppressed viral adsorption in an assay, reducing titers by 3.55 log TCID₅₀ ml⁻¹, which highlights its anti-adsorption activity against transmissible gastroenteritis virus [78]. Another study showed that *Curcuma longa* extract represses HBV replication through enhancing the level of p53 protein [79]. Then, three curcuminoids compounds, curcumin, demethoxycurcumin and bisdemethoxycurcumin, could serve as potential supplementary agents in preventing and treating diseases caused by influenza viruses. These compounds exhibited the inhibitory activity against novel influenza strains, including H9N2, H1N1, and the oseltamivir-resistant novel H1N1 (H274Y mutant) expressed in 293 T cells [80].

Other activities

The synergistic application of a mixture composed of four compounds (curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin) derived from

turmeric significantly enhanced anti-nematicidal activity [81]. *ar*-Turmerone and (*E*)-labda-8(17),12-diene-15,16-dial, derived from the volatile oil of turmeric, exhibited potential mosquitocidal and anti-microbial activity, respectively. *ar*-Turmerone demonstrated a mosquitocidal effect, with an LD₁₀₀ of 50 µg/mL against *Aedes aegyptii* larvae, while (*E*)-labda-8,12-diene-15,16-dial demonstrated significant anti-fungal efficacy against *Candida parapsilosis* and *Candida krusei* at a concentration of 25 µg/mL [82]. Drug-metabolizing enzymes, particularly cytochrome P450 enzyme (CYPs), are recognized as significant contributors to adverse drug reactions and therapeutic failures, as they metabolize many currently available therapeutic agents. The sesquiterpene compound (4*S*,5*S*)-(+)-germacrone-4,5-epoxide demonstrated significantly enhanced CYP3A4 inhibition compared to curcumin analogs, exhibiting a potent IC₅₀ value of 1.0 µM. This inhibitory activity represents a substantial improvement over both curcumin (IC₅₀=14.9 µM) and demethoxycurcumin (IC₅₀=7.0 µM), with approximately 15-fold and sevenfold greater potency, respectively. Furthermore, the (4*S*,5*S*)-(+)-germacrone-4,5-epoxide compound exhibited the most potent inhibitory activity against CYP1A2, CYP2C9, and CYP3A4 [83]. *Ar*-turmerone, identified as the main volatile component in turmeric rhizome, demonstrated significant dose-dependent inhibition against both α-glucosidase (IC₅₀=0.28 µg/mL) and α-amylase (IC₅₀=24.5 µg/mL) [84]. Additionally, in irinotecan-induced nude mice, curcumin administration significantly alleviated diarrhea symptoms, restored the structural integrity of intestinal mucosa, and upregulated the expression of PRDX4 and P4HB [85]. Moreover, turmeric was reported to possess promising anti-aging activity to maintain healthy aging. It was demonstrated that dietary supplementation with 0.5% turmeric effectively attenuated age-related physiological decline in *Drosophila melanogaster*, primarily through preservation of β-tubulin protein level in cerebral tissue [86].

Clinical application

Randomized controlled trials (RCTs) are crucial for validating the efficacy of drugs. The current progress of turmeric application in clinical studies demonstrates promising results. In RCTs, turmeric could bring clinical benefits in type 2 diabetes, metabolic syndrome, knee osteoarthritis, hemodialysis, etc. (Table 2). Additionally, In TCM clinical practice, turmeric is typically not used alone but combined with other medicines to form prescriptions.

Table 2 Clinical studies of turmeric

| Rank | Disease | Sample sizes | Test period | Drug | Result | Ref/NCT no | Refs |
|------|---|--------------|-------------|---|---|-----------------------|-------|
| 1 | Knee osteoarthritis (Grade 2 and 3) | 60 | 4 weeks | Curcumin (600 mg/day), gingerols (15 mg/day), piperine (7.5 mg/day) | ↓PGE2 | IRCT2017070511763 N32 | [104] |
| 2 | Knee osteoarthritis | 144 | 6 weeks | Turmeric extract (BCM-95®) (1000 mg/day) | ↓CRP, TNF-α | CTRI/2017/02/007962 | [97] |
| 3 | Knee joint pain | 68 | 1 week | B-Turmax® (Turmeric extracts 500 mg/day + curcuminoid complex 19.5 mg/day) | ↓Knee joint pain, CRP | NCT03202901 | [105] |
| 4 | Hemodialysis | 21 | 12 weeks | Turmeric (3 g/day); turmeric/piperine (3 g turmeric/day + 2 mg piperine/day) | ↓MDA, ferritin, GPx | no. 2.594.918 | [106] |
| 5 | Vitiligo | 24 | 4 months | Turmeric | ↓size of lesions; ↑lesion's appearance, patient's satisfaction score | IRCT20180910040994N1 | [107] |
| 6 | Non-alcoholic fatty liver disease | 92 | 12 weeks | Turmeric supplementation (3 g/day); turmeric and chicory seed supplementation (3 g/day turmeric + infused 9 g/day chicory seed) | ↓BMI, WC, (TG/HDL-C)/(LDL-C/HDL-C) ratio; ↑HDL-C | IRCT201406183664N12 | [94] |
| 7 | Psoriasis | 40 | 9 weeks | Turmeric tonic | ↓Erythema, PASI score; ↑patients' quality of life | IRCT201604183106N30 | [108] |
| 8 | Premenstrual syndrome | 123 | 3 months | Curcuminoid (500 mg/day) | ↓PSS scores, dysmenorrhea pain | IRCT20191112045424N1 | [109] |
| 9 | Oral submucous fibrosis | 35 | 3 months | Kali Haldi (6 mg/day) + Aloe vera gel (6 mg/day) | ↓Burning sensation; ↑cheek flexibility, tongue protrusion | – | [110] |
| 10 | Knee osteoarthritis | 150 | 90 days | Turmeric rhizome extract (186.68 or 280.02 mg/day) | ↓PGADA, pain, KOOS | ISRCTN12345678 | [111] |
| 11 | Non-alcoholic fatty liver disease | 46 | 12 weeks | Turmeric powder (3000 mg/d) | ↓Glucose, insulin, HOMA-IR, leptin | IRCT201406183664N12 | [93] |
| 12 | Knee osteoarthritis | 101 | 8 weeks | Curcumin extract (Curcugen®) (1000 mg/d) | ↓KOOS knee pain score, numeric knee pain ratings; ↑timed up-and-go test, 6-min walk test, JOA total score | ACTRN12620000976987 | [99] |
| 13 | Hemodialysis | 50 | 8 weeks | Turmeric capsule (1500 mg/day) | ↓MDA; ↑CAT, albumin | – | [112] |
| 14 | Self-reported digestive complaints | 77 | 8 weeks | Curcugen™ (500 mg/day) | ↓GSR score, DASS-21 anxiety score | ACTRN12619001236189 | [113] |
| 15 | Hyperlipidemic type 2 diabetes | 75 | 8 weeks | Powdered rhizome of turmeric (2100 mg/d) | ↓BMI, TG, TC | IRCT201204162602 | [114] |
| 16 | Primary dysmenorrhea | 128 | – | Turmeric (500 mg/d) | ↓Pain | IRCT20141025019669N9 | [115] |
| 17 | Hemodialysis | 100 | 8 weeks | Turmeric (1500 mg/day, containing 66.3 mg curcumin/day) | ↓Hs-CRP, pruritus scores | NCT01037595 | [116] |
| 18 | Oral cancer (undergone radical surgery) | 60 | 6 weeks | Bio-enhanced turmeric formulation (1 or 1.5 g/day) | ↓chemoradiotherapy-induced severe oral mucositis, dysphagia, oral pain, dermatitis | CTRI/2015/12/006413 | [101] |
| 19 | Oral dysfunctions among head and neck cancer | 92 | – | – | ↓Oral mucositis and associated oral dysfunctions | CTRI/2018/06/014367 | [103] |
| 20 | Chronic kidney disease (undergoing peritoneal dialysis) | 24 | 12 weeks | Curcumin (1500 mg/day, with 98.42% total curcuminoids) | ↓MDA, lipid peroxidation | NCT04413266 | [117] |
| 21 | Head and neck cancer | 80 | 7 weeks | Turmeric capsule (1200 mg/day) | ↓Radiation-induced oral mucositis, intolerable mucositis, body weight | – | [118] |

Table 2 (continued)

| Rank | Disease | Sample sizes | Test period | Drug | Result | Ref/NCT no | Refs |
|------|---|--------------|-------------|--|---|-----------------------------------|-------|
| 22 | Overt type 2 diabetic nephropathy | 40 | 2 months | Turmeric (1500 mg/day, 66.3 mg was curcumin) | ↓TGF-β, IL-8, urinary protein excretion | – | [119] |
| 23 | Mild to moderate elevated alanine transaminase levels | 48 | 12 weeks | Fermented turmeric powder (3.0 g/day) | ↓ALT, AST | NCT01634256 | [120] |
| 24 | Metabolic syndrome | 250 | 8 weeks | Turmeric (2.4 g/day) | ↓LDL-C, CRP | ACTRN12613001053718 | [121] |
| 25 | Eczema | 360 | 3 months | Indian pennywort, Walnut and Turmeric | Semi quantitative scores of erythema and oedema reduced; itching relieved | – | [122] |
| 26 | COVID-19 | 68 | 2 weeks | Nanocurcumin (160 mg/day) | ↓Coughs, fatigue, myalgia, oxygen demand, oxygen usage, and respiratory rate minimized; ↑SpO ₂ | IRCT20211126053183N1 | [123] |
| 27 | Type 2 diabetes | 227 | 12 months | Curcuminoids (1500 mg/day) | ↓Pulse wave velocity, LDL-C, sd LDL-C, CRP, IL-1β, IL-6, TNF-α | TCTR20140303003 | [87] |
| 28 | Hemodialysis | 71 | 12 weeks | Turmeric (1500 mg/day, containing 66.3 mg curcumin/day) | ↓hs-CRP, IL-6, TNF-α; ↑albumin | – | [124] |
| 29 | Osteoarthritis | 30 | 3 months | Sinacurcumin® (80 mg/day) | ↓Visual Analog Score, CRP, CD4 ⁺ T cells, CD8 ⁺ T cells | NCT03715140 | [98] |
| 30 | Type 2 diabetes | 100 | 12 weeks | Curcumin (1000 mg/day) + piperine (10 mg/day) | ↓Leptin, (TNF-α + leptin)/adiponectin ratio; ↑adiponectin | IRCT201505301165N4 | [125] |
| 31 | Type 2 diabetes | 71 | 120 days | <i>Curcuma longa</i> L. (500 mg/d) + piperine (5 mg/d) | ↓Glycaemia, glycated haemoglobin, HOMA index, TG | RBR-6r7w8k | [88] |
| 32 | Metabolic syndrome with obesity | 94 | 90 days | Calebin A (50 mg/day) + piperine (6 mg/day) | ↓Body weight, waist circumference, BMI, LDL-C, TG, leptin, CRP; ↑HDL-C | CTRI/2021/09/036495 | [96] |
| 33 | Primary knee osteoarthritis | 40 | 6 weeks | Curcuminoid (1500 mg/day) + piperine (15 mg/day) | ↑SOD, GSH; ↓MDA | – | [126] |
| 34 | Type 2 diabetes | 118 | 12 weeks | Curcuminoids (1000 mg/day) + (piperine 10 mg/day) | ↓TC, non-HDL-C, Lp(a), ↑HDL-C | IRCT201505301165N4 | [89] |
| 35 | Metabolic syndrome | 66 | 12 weeks | curcumin (500 mg/day) | ↓Body weight, Pulse wave velocity | IRCT20180619040151N2 | [127] |
| 36 | Chronic kidney disease | 31 | 3 months | Curcumin (100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric/week) | ↓NF-κB mRNA, hsCRP | NCT03475017 | [100] |
| 37 | Metabolic syndrome | 50 | 12 weeks | Nano-curcumin (80 mg/day) | ↓TG, HOMA-β | IRCT20150815023617N3, NCT03534024 | [95] |
| 38 | Sarcopenia | 30 | 3 months | Cureit™ (500 mg/day) | ↑Handgrip strength, weight-lifting capacity | CTRI/2018/05/014176 | [128] |
| 39 | Laparoscopic gynecologic surgery | 60 | 3 days | Curcuminoid extract (1000 mg/day) | ↓Pain severity | TCTR20180215001 | [129] |
| 40 | Liver cirrhosis | 60 | 3 months | Curcumin (1000 mg/day) | ↓Model for end-stage liver disease (MELD) (i), MELD, MELD-Na | IRCT20180802040678N1 | [130] |
| 41 | Non-alcoholic fatty liver disease | 80 | 2 months | Curcumin (250 mg/day) | ↓The grade of hepatic steatosis, AST, hepatic steatosis and enzymes | IRCT201505232381N1 | [131] |
| 42 | Polycystic ovarian syndrome | 67 | 3 months | Curcumin (1500 mg/day) | ↑PGC1α, Gpx enzyme | IRCT20091114002709N50 | [132] |

Table 2 (continued)

| Rank | Disease | Sample sizes | Test period | Drug | Result | Ref/NCT no | Refs |
|------|--|--------------|-------------|---|--|----------------------|-------|
| 43 | Liver cirrhosis | 58 | 12 weeks | Curcumin (1000 mg/day) | ↑CLDQ domains; Physical and Mental health (Total) scores, most of SF-36 domains; ↓LDL 2.0 domains | IRCT20180802040678N1 | [133] |
| 44 | Type 2 diabetes | 229 | 12 months | Curcumin (1500 mg/day) | ↓Fasting blood glucose, HbA1c, HOMA-IR, leptin, BMI; ↑HOMA-β, adiponectin | 20140303003 | [90] |
| 45 | Knee osteoarthritis | 140 | 28 days | Curcuminoid complex (1000 mg/day) + diclofenac (100 mg/day) | ↓Pain; ↑quality of life | ISRCTN10074826 | [134] |
| 46 | Type 2 diabetes | 114 | 3 months | <i>Curcuma longa</i> L. (400 mg/day) | ↓Carotid-femoral pulse wave velocity, left brachial-ankle pulse wave velocity, aortic augmentation pressure, aortic augmentation index, aortic augmentation index at heart rate 75 | CTRI/2016/10/007401 | [91] |
| 47 | Type 2 diabetes | 80 | 8 weeks | Nano-curcumin (80 mg/day) | ↓HbA1c, FBS, total score of neuropathy, total reflex score | IRCT20140413017254N5 | [92] |
| 48 | Nonalcoholic fatty liver diseases | 55 | 8 weeks | Curcuminoids (500 mg/day) + piperine (5 mg/day) | ↓Weight, TNF-α, MCP-1, EGF | – | [135] |
| 49 | Overweight or prehypertension/mild hypertension | 90 | 12 weeks | <i>Curcuma longa</i> L. (900 mg/day) | ↓CRP, TNF-α, IL-6, sVCAM-1, glucose, HbA1c, TG; ↑HDL-C | – | [136] |
| 50 | Type 2 diabetes | 44 | 10 weeks | Curcumin (1500 mg/day) | ↓TG, CRP, ↑adiponectin | NCT02529969 | [137] |
| 51 | β-thalassemia major | 68 | 12 weeks | Curcumin (1000 mg/day) | ↓NTBI, ALT, AST | IRCT2016053028165N1 | [138] |
| 52 | Chronic prostatitis/ chronic pelvic pain syndrome type III | 48 | 1 month | Curcumin extract (350 mg) + Calendula extract 80 mg (1 suppository/die/month) | ↓NIH-CPSI, IIEF-5, PEDT, peak flow, VAS | – | [139] |
| 53 | Cancer | 80 | 8 weeks | Bioavailability-boosted curcuminoids preparation (180 mg/day) | ↓TNF-α, TGFβ, IL-6, substance P, hs-CRP, CGRP, MCP-1; ↑Quality of life | – | [102] |
| 54 | Osteoarthritis of knee | 160 | 120 days | <i>Curcuma longa</i> L. (500 mg/day) + Diclofenac (50 mg/day) | ↑IL-1β, ROS, MDA | CTRI/2015/12/006438 | [140] |
| 55 | Sulfur mustard | 89 | 4 weeks | Curcuminoids (1500 mg/day) + piperine (15 mg/day) | ↑GSH, CAT, SGRO; ↓MDA | – | [141] |

Treatment of metabolic diseases

Clinical evidences have demonstrated that turmeric supplementation could improve diabetes and its complications. In obese patients with type 2 diabetes individuals receiving curcuminoids supplementation (1500 mg/day) for 12 months, the cardiometabolic risk biomarkers such as small dense low-density lipoprotein cholesterol and low-density lipoprotein cholesterol reduced, along with decreased levels of inflammatory markers including IL-1 β , IL-6, hs-CRP, and TNF- α [87]. A recent investigation revealed that turmeric supplementation (500 mg/day with piperine 5 mg/day) within a course of 120 days significantly reduced fasting plasma glucose, glycated hemoglobin, homeostatic model assessment of insulin resistance (HOMA-IR) and triglycerides [88]. Moreover, curcuminoids supplement can reduce the diabetes associated atherogenic risks. In a 12-week intervention study, 59 participants were administered curcuminoids (1000 mg/day with piperine 10 mg/day), while 59 participants were given placebo. The study revealed that curcuminoids can significantly reduce serum concentrations of key atherogenic lipid profiles, such as non-high-density lipoprotein cholesterol (non-HDL-C) and lipoprotein(a) [Lp(a)] [89]. Another study (for 12 months) included 229 individuals indicated that curcuminoids supplementation (1500 mg/day) demonstrated significant improvement in pancreatic β -cell function along with notable reduction in both insulin resistance and body weight compared with the placebo group [90]. Srinivasan et al. showed that 400 mg/day of turmeric intake for 3 months decreased arterial stiffness when compared to that of the placebo group [91]. In addition, it has been reported that nano-curcumin supplementation reduced fasting blood glucose, glycated hemoglobin, total neuropathy score, and total reflex score compared to the placebo group [92].

Furthermore, according to an investigation on the effects of turmeric on serum glucose parameters and leptin levels in patients with nonalcoholic fatty liver disease (NAFLD), 46 individuals were given supplements of 3000 mg/day turmeric powder or placebo for 12 weeks. The findings revealed significant decrease in fasting serum glucose, insulin levels, HOMA-IR scores, and leptin levels [93]. Also, oral turmeric supplementation at a dosage of 3 g/day among patients with non-alcoholic fatty liver disease (NAFLD) led to significant reduction in the serum TG/HDL-C and LDL-C/HDL-C ratio [94]. Besides, in metabolic syndrome patients receiving 80 mg/day nano-curcumin for 12 weeks, the levels of triglyceride and HOMA- β were significantly improved [95]. Another study in metabolic syndrome individuals with obesity, 94 individuals were administered Calebin A, a minor bioactive phytochemical from turmeric. The study indicated that Calebin A could significantly reduce circulating

leptin and C-reactive protein levels [96]. Overall, studies conducted to date have indicated that turmeric improved the related index of glucolipid metabolism including glycaemia, glycated haemoglobin, HOMA index, insulin resistance, triglycerides, and non-high-density lipoprotein cholesterol, and reduced inflammation.

Treatment of inflammatory diseases

Turmeric has proven to be very effective in many types of inflammatory diseases. One study suggested that turmeric extract was as effective as paracetamol in reducing pain and other symptoms associated with knee osteoarthritis. Furthermore, it demonstrated a more favorable safety profile and greater efficacy in lowering inflammatory biomarkers, specifically CRP and TNF- α levels [97]. In another study, thirty patients were randomly assigned to two groups and received either Sinacurcumin[®] (80 mg daily) or a placebo for a period of three months. The data demonstrated that curcumin significantly decreased visual analogue scale scores, C-reactive protein, and immunological parameters including CD4⁺ and CD8⁺ T cells, Th17 cells and B cells frequency [98]. A follow-up study (for 8 weeks) included 101 individuals at risk of knee osteoarthritis. The study indicated that participants in the Curcugen[®] (curcumin extract) group experienced significant decreases in their KOOS knee pain scores and numeric knee pain ratings [99]. In chronic kidney disease patients undergoing hemodialysis, a three-month treatment with curcumin supplementation (administered daily as 2.5 g turmeric dissolved in 100 mL orange juice with 12 g carrot) resulted in decreased inflammatory biomarkers, NF- κ B mRNA expression and hsCRP protein concentration, suggesting that regular curcumin intake may modulate inflammatory pathways in clinical populations [100].

Treatment of cancers

Clinical studies have confirmed the positive clinical efficacy of turmeric in cancers. In a randomized double-blinded placebo-controlled trial (n=60), researchers evaluated the effects of turmeric formulation capsules in patients with oral cancer. The study revealed that oral administration of curcumin-formulated capsules significantly reduced chemoradiotherapy-induced severe oral mucositis, dysphagia, pain, and dermatitis in oral cancer patients [101]. Another study revealed that curcuminoid supplementation (180 mg/day) within a course of 8 weeks significantly improved the health-related quality of life and suppressed systemic inflammation in patients with solid tumors [102]. In addition, turmeric mouthwash exhibited superior efficacy to benzydamine mouthwash in mitigating both the clinical severity of oral mucositis and related functional impairments among patients

undergoing treatment for head and neck carcinoma [103].

Application of *Curcuma longa* products

Curcuma longa has been cherished worldwide because of its medicinal and nutritional value and exhibits broad potential across various industries, such as pharmaceutical industry, food industry, cosmetic industry. Currently, there are 34280 patents related to turmeric worldwide (<https://www.lens.org/>). The United States has the largest number of patents, accounting for forty-four percent, followed by China. These patents primarily focused on medicine, health food, herbal dietary supplement, cosmetics, and other applications. Based on the *Pharmacopeia of the People's Republic of China (Edition 2020)* and *Traditional Chinese medicine preparations*, a total of 29 turmeric-containing prescriptions were included, involving Jianghuangxiaocuo liniments, Wujunzhi dan tablets, Jiangzhitongluo soft capsules, Wuhuangyangyin particles, Jinzhong pills, Yuxuebi capsules, Binghuangfule ointment, Ruyijinhuang powders, Fengtongan capsules, Biwen powders, Jiuweigantai capsules, Xiaotong plasters, Dieda pills, Huazhenghuisheng tablets, Taijishengjiang pills, Zhongmanfenxiao pills, Qingyili dan particles, Shangshijietong plasters, Chansuzhentong plasters, Huangjinboyao wines, Shulereyunji, Guanjiezhentong plasters, Chenxiangshuyu pills, Lidanzhitong tablets, Jingzhiwujiapi wines, Chenxiangshuyu tablets, Yuxuebi particles, Shanxuanjing tinctures, and Wudizhitong liniments (Table 3). Among them, Jiangzhitongluo soft capsules is only composed of turmeric extract. The others, such as Jianghuangxiaocuo liniments, Wujunzhi dan tablets, Wuhuangyangyin particles, all include many TCM herbs or components, with a wide range of clinical efficacy.

In the food industry, the health-promoting properties of turmeric rhizomes have garnered considerable attention. According to the State Administration for Market Regulation, there are totally 63 health foods containing turmeric, including 41 capsules, 18 tablets, 1 particle, 1 powder, 1 drink, and 1 tea, such as haishenjianghuang soft capsule, jianghuanghuangqi tablet, jianghuangbaishaorenshe particle, jianghuangyuganzihezi powder and others. Furthermore, turmeric is also used as food additives. According to the “GB 2760–2014 National Food Safety Standard for Use of Food Additives” in China, the maximum allowable amount of curcumin for frozen drinks is 0.15 g/kg, for cocoa products, chocolate & chocolate products (including chocolate & chocolate products with cocoa butter alternatives), and candies is 0.01 g/kg, for batter, coating flour, and fried powder is 0.3 g/kg, for instant noodles products and seasoning syrup is 0.5 g/kg, for

compound seasoning is 0.1 g/kg, carbonated drinks is 0.01 g/kg (GB 2760–2014 National Food Safety Standard for Use of Food Additives). Besides, it is worth noting that in most western countries, Turmeric has been extensively regarded as dietary supplement for diverse conditions, including arthritis, respiratory infections, digestive disorders, depression, liver disease, allergies, and many others, with many forms, such as tablet, capsule, particle, soft gel, powder, bar, liquid, etc. In the US mainstream multi-outlet channel, total sales of turmeric increased steadily from 2013 to 2022. In the US natural channel, turmeric was the top-selling primary ingredient from 2013 until 2018, when it dropped to the second position due to a surge of interest in cannabidiol. In 2022, turmeric regained its top rank in the natural channel.

In the cosmetics industry, turmeric has gained considerable popularity due to its potent anti-inflammatory activity, anti-oxidant activity, and anti-bacterial activity. According to records, turmeric is considered one of the earliest cosmetic because it traditionally has been smeared on the skin by Indian women [142]. One study suggested that a nanosphere loaded with curcumin enhanced the mobilization of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), thereby promoting cutaneous wound repair [143]. Additionally, in vitro testing on ‘pumpless skin-on-a-chip’ with turmeric leaf extract, the enhancement of the epidermal barrier function demonstrated significant anti-aging efficacy [144]. The “Catalogue of Used Cosmetic Ingredients (2021 Edition)” released by the National Medical Products Administration includes over 8,965 used cosmetic ingredients, with 10 cosmetic ingredients related to turmeric, including *curcuma longa* root, *curcuma longa* root powder, *curcuma longa* rhizome extract, *curcuma longa* root water, *curcuma longa* root extract, *curcuma longa* root oil, *curcuma longa* extract, *curcuma longa* leaf extract, curcumin, and tetrahydrocurcumin (The “Catalogue of Used Cosmetic Ingredients (2021 Edition)”). Today, Cosmetics brands containing turmeric are spread all over the world, as CN formula, boben, home’ jubi lant and voelga in China, origins, sunday riley, first aid beauty and Kiehl’s in the United States of America, forest essentials and himalaya in India.

Future perspectives

Considering the applications of turmeric in various fields around the world, the establishment of an international standard for turmeric rhizome is necessary to guarantee the clinical effectiveness, safety and controllability in global commerce and trade. Our team and professor Wang Mei from Leiden university jointly initiate the

Table 3 Prescriptions containing turmeric in TCM clinical applications

| Rank | Prescription name | Prescription source | Prescription compositions | Action of prescription |
|------|-------------------------------|--|---|--|
| 1 | Jianghuangxiaocuo liniments | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Curcuma longa</i> , <i>Paris polyphylla</i> , <i>Polygonum perfoliatum</i> , <i>Chenopodium ambrosioides</i> , <i>Solidago decurrens</i> , <i>Gynostemma pentaphyllum</i> , <i>Zingiber corallinum</i> | Used for acne caused by damp heat stagnation, and seborrheic dermatitis |
| 2 | Wujunzhidan tablets | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Prunus mume</i> , <i>Rheum officinale</i> , <i>Citrus medica</i> , <i>Citrus aurantium</i> , <i>Origanum vulgare</i> , <i>Gardenia jasminoides</i> , <i>Glycyrrhiza uralensis</i> , <i>Areca catechu</i> , <i>Clematis chinensis</i> , <i>Curcuma longa</i> | Used for costal pain and biliary distension caused by damp-heat in the liver and gallbladder, presenting with symptoms such as costal rib distending pain, fever, and dark yellow urine; also applicable for patients with cholecystitis, biliary tract infection, or postoperative conditions of the biliary tract who exhibit the above-mentioned symptoms |
| 3 | Jiangzhitongluo soft capsules | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Curcuma longa</i> extract | Used for hyperlipidemia with Qi stagnation and blood stasis syndrome, characterized by costal and epigastric distending pain, precordial stabbing pain, chest oppression, ecchymosis or petechiae on the tip or margin of the tongue, and string-like or choppy pulse |
| 4 | Wuhuangyangyin particles | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Coptis chinensis</i> , <i>Hedysarum polybotrys</i> , <i>Rehmannia glutinosa</i> , <i>Curcuma longa</i> , <i>Scutellaria baicalensis</i> | Used for diabetes mellitus characterized by phlegm-dampness stagnation and Qi-Yin deficiency syndrome, symptoms include polydipsia with frequent drinking, polyphagia with increased appetite, polyuria with frequent urination, heaviness and fatigue in the head and body, nausea and sputum production, fatigue and weakness, shortness of breath and laziness to speak, spontaneous sweating and night sweats, palpitations and insomnia, obesity, dry throat and mouth, irritability and heat intolerance, dark red urine and constipation, etc |
| 5 | Jinfozhitong Pills | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Paeonia lactiflora</i> , <i>Corydalis yanhushuo</i> , <i>Panax notoginseng</i> , <i>Curcuma wenyujin</i> , <i>Citrus medica</i> , <i>Curcuma longa</i> , <i>Glycyrrhiza uralensis</i> | Used for epigastric pain due to Qi and blood stasis, dysmenorrhea, and pain caused by peptic ulcer and chronic gastritis |
| 6 | Yuxuebei capsules | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Boswellia carterii</i> , <i>Commiphora myrrha</i> , <i>Carthamus tinctorius</i> , <i>Clematis chinensis</i> , <i>Cyathula officinalis</i> , <i>Gyperus rotundus</i> , <i>Curcuma longa</i> , <i>Angelica sinensis</i> , <i>Salvia miltiorrhiza</i> , <i>Ligusticum chuansiang</i> , <i>Astragalus membranaceus</i> | Used for arthralgia caused by blood stasis obstructing the collaterals, characterized by severe muscle and joint pain, tenderness on palpation, fixed location, and possible presence of nodules or ecchymosis |
| 7 | Binghuangfule ointments | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Rheum officinale</i> , <i>Curcuma longa</i> , <i>Sulfur</i> , <i>Scutellaria baicalensis</i> , <i>Glycyrrhiza uralensis</i> , <i>Borneolum Syntheticum</i> , <i>Mentholum</i> | Used for skin itching caused by damp heat accumulation or blood heat and dryness; Pruritic skin diseases such as neurodermatitis, eczema, tinea pedis, and psoriasis are seen in the above syndromes |
| 8 | Ruyijinhuang powders | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Curcuma longa</i> , <i>Rheum officinale</i> , <i>Phellodendron chinense</i> , <i>Actinolydes lancea</i> , <i>Magnolia officinalis</i> , <i>Citrus reticulata</i> , <i>Glycyrrhiza uralensis</i> , <i>Arisaema erubescens</i> , <i>Angelica dahurica</i> , <i>Trichosanthes kirilowii</i> | Used for erysipelas and furunculosis caused by heat-toxin stagnation in the skin, characterized by erythema (redness), edema (swelling), heat, and tenderness of the skin. It is also applicable for contusions and sprains |

Table 3 (continued)

| Rank | Prescription name | Prescription source | Prescription compositions | Action of prescription |
|------|--------------------------|--|---|--|
| 9 | Fengtongtan capsules | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Stephania tetrandra</i> , <i>Tetrapanax papyrifer</i> , <i>Cinnamomum cassia</i> , <i>Curcuma longa</i> , <i>Gypsum fibrosum</i> , <i>Coix lacryma-jobi</i> , <i>Chaenomeles speciosa</i> , <i>Erythrina variegata</i> , <i>Lonicera japonica</i> , <i>Phellodendron chinense</i> , <i>Talcum pulvis</i> , <i>Forsythia suspensa</i> | Used for arthralgia caused by damp-heat obstructing the collaterals, characterized by erythema, edema (swelling), heat, and tenderness of the joints, as well as myalgia (muscle soreness). It is also applicable for rheumatic arthritis presenting with the above-mentioned symptoms |
| 10 | Biwen powders | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Santalum album</i> , <i>Lysimachia foenum-graecum</i> , <i>Angelica dahurica</i> , <i>Lysimachia capillipes</i> , <i>Curcuma longa</i> , <i>Rosa rugosa</i> , <i>Nardostachys jatamansi</i> , <i>Eugenia caryophyllata</i> , <i>Aucklandia lappa</i> , <i>Artificial moschus</i> , <i>Borneolum syntheticum</i> , <i>Cinnabaris</i> , <i>Mentholum</i> | Used for dizziness, headache, nasal congestion, nausea, vomiting, motion sickness and seasickness caused by summer heat |
| 11 | Jiaweigantai capsules | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Panax notoginseng</i> , <i>Curcuma wenyujin</i> , <i>Tribulus terrestris</i> , <i>Curcuma longa</i> , <i>Rheum officinale</i> , <i>Scutellaria baicalensis</i> , <i>Scolopendria subspinipes mutilans</i> , <i>Dioscorea opposita</i> , <i>Schisandra chinensis</i> | Used for costal pain or stabbing pain, depressive symptoms and irritability, anorexia, epigastric fullness and distension after eating, disordered bowel movements, and subcostal masses caused by Qi stagnation and blood stasis combined with liver depression and spleen deficiency |
| 12 | Xiaotong plasters | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Lamiophlomis rotata</i> , <i>Curcuma longa</i> , etc | Used for acute and chronic sprains, bruises, bone hyperplasia, rheumatism and rheumatoid pain, stiff neck, frozen shoulder, lumbar muscle strain and old injuries |
| 13 | Dieda pills | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Panax notoginseng</i> , <i>Angelica sinensis</i> , <i>Paeonia lactiflora</i> , <i>Prunus persica</i> , <i>Carthamus tinctorius</i> , <i>Dae-monorops diaco</i> , <i>Siphonostegia chinensis</i> , <i>Drynaria fortunei</i> , <i>Dipsacus asper</i> , <i>Caesalpinia sappan</i> , <i>Paeonia suffruticosa</i> , <i>Boswellia carterii</i> , <i>Commiphora myrrha</i> , <i>Curcuma longa</i> , etc | Used for traumatic injuries, rupture of muscles and tendons, fractures, hematoma and swelling with pain, acute lumbar sprain |
| 14 | Huazhenghuisheng tablets | Pharmacopoeia of the People's Republic of China (Edition 2020) | <i>Leonurus japonicus</i> , <i>Carthamus tinctorius</i> , <i>Zanthoxylum bungeanum</i> , <i>Hirudo nipponica</i> , <i>Angelica sinensis</i> , <i>Caesalpinia sappan</i> , <i>Sparganium stoloniferum</i> , <i>Anemone raddeana</i> , <i>Ligusticum chuansiang</i> , <i>Dalbergia odorifera</i> , <i>Cyperus rotundus</i> , <i>Panax ginseng</i> , <i>Alpinia officinarum</i> , <i>Curcuma longa</i> , etc | Used for accumulation caused by blood stasis and internal obstruction, dry blood tuberculosis in women, postpartum blood stasis, and abdominal pain and refusal to press |
| 15 | Taiji shengjiang pills | Traditional Chinese medicine preparations (Volume 2) | <i>Bombyx mori</i> , <i>Rheum officinale</i> , <i>Cryptotympana pus-tulata</i> , <i>Bambusa textilis</i> , <i>Arisaema cum bile</i> , <i>Curcuma longa</i> , <i>Borneolum syntheticum</i> | Used for pediatric epidemics, fever and convulsions, swollen cheeks, stagnation of milk and food, phlegm and heat constipation |
| 16 | Zhongmanfexiao pills | Traditional Chinese medicine preparations (Volume 3) | <i>Poria cocos</i> , <i>Polyporus umbellatus</i> , <i>Scutellaria baicalensis</i> , <i>Curcuma longa</i> , <i>Codonopsis pilosula</i> , <i>Attractylodes macrocephala</i> , <i>Pinellia ternata</i> , <i>Citrus reticulata</i> , <i>Anemarrhena asphodeloides</i> , <i>Citrus aurantium</i> | Used for spleen deficiency and qi stagnation, dampness and heat stagnation, food and lodging water storage, abdominal distension and pain, heat and bitterness, full and noisy, and unfavorable stool |
| 17 | Qingyilidan particles | Traditional Chinese medicine preparations (Volume 4) | <i>Bupleurum chinense</i> , <i>Corydalis yanhushuo</i> , <i>Curcuma longa</i> , <i>Paeonia suffruticosa</i> , <i>Paeonia lactiflora</i> , <i>Ostrea gigas</i> , <i>Lonicera japonica</i> , <i>Rheum officinale</i> | Used for acute pancreatitis, acute gastritis, and other symptoms |
| 18 | Shangshijietong plasters | Traditional Chinese medicine preparations (Volume 5) | <i>Angelica pubescens</i> , <i>Angelica dahurica</i> , <i>Aconitum cammichellii</i> , <i>Aconitum kusnezoffii</i> , <i>Cinnamomum tamala</i> , <i>Vaccaria segetalis</i> , <i>Curcuma longa</i> , etc | Used for myalgia and arthralgia caused by wind-cold-damp pathogens, shoulder and lumbar soreness, joint pain, and traumatic injuries |

Table 3 (continued)

| Rank | Prescription name | Prescription source | Prescription compositions | Action of prescription |
|------|---------------------------|---|--|---|
| 19 | Chansuzhentong plasters | Traditional Chinese medicine preparations (Volume 5) | <i>Bufo bufo gargarizans</i> , <i>Strychnos nux-vomica</i> , <i>Aconitum carmichaelii</i> , <i>Arisaema erubescens</i> , <i>Realgar</i> , <i>Angelica dahurica</i> , <i>Curcuma longa</i> , etc | Used for analgesia and dissipation of various swellings, also used for myofascial pain syndrome, osteophytes, osteoarthritis, and other conditions that cause pain |
| 20 | Huangjinboyao wines | Traditional Chinese medicine preparations (Volume 6) | <i>Angelica sinensis</i> , <i>Carthamus tinctorius</i> , <i>Citrus medica</i> , <i>Ligusticum chuansiong</i> , <i>Illicium difengpi</i> , <i>Myristica fragrans</i> , <i>Cinnamomum cassia</i> , <i>Curcuma longa</i> , etc | Used for paresthesia of the limbs), myalgia and arthralgia, and epigastric coldness with fullness |
| 21 | Shulereyunji | Traditional Chinese medicine preparations (Volume 6) | <i>Aconitum carmichaelii</i> , <i>Sinapis alba</i> , <i>Angelica pubescens</i> , <i>Ligusticum chuansiong</i> , <i>Oleum terebinthinae</i> , <i>Oleum eucalypti</i> , <i>Asarum heterotropoides</i> , <i>Artemisia argyi</i> , <i>Atractylodes Lancea</i> , <i>Cinnamomum camphora</i> , <i>Curcuma longa</i> , etc | Used for myalgia and arthralgia caused by wind-cold-damp stagnation, lumbar muscle pain, lumbar muscle strain, periarthritis of the shoulder, and rheumatic arthritis |
| 22 | Guanjiezhentong plasters | Traditional Chinese medicine preparations (Volume 7) | <i>Capsicum annuum</i> , <i>Cinnamomum cassia</i> , <i>Aconitum carmichaelii</i> , <i>Aconitum kusnezoffii</i> , <i>Asarum heterotropoides</i> , <i>Curcuma longa</i> , etc | Used for myalgia, arthralgia, and soft tissue injuries such as sprains |
| 23 | Chenxiangshuyi pills | Traditional Chinese medicine preparations (Volume 10) | <i>Aquilaria sinensis</i> , <i>Aucklandia lappa</i> , <i>Magnolia officinalis</i> , <i>Citrus aurantium</i> , <i>Corydalis yanhushuo</i> , <i>Amomum kravanh</i> , <i>Citrus reticulata</i> , <i>Amomum villosum</i> , <i>Cyperus rotundus</i> , <i>Citrus reticulata</i> , <i>Bupleurum chinense</i> , <i>Curcuma longa</i> , etc | Used for epigastric fullness and bloating, epigastric pain, vomiting of acid, indigestion, anorexia, and dysphoria |
| 24 | Lidanzhitong tablets | Traditional Chinese medicine preparations (Volume 11) | <i>Isatis indigotica</i> , <i>Taraxacum mongolicum</i> , <i>Artemisia scoparia</i> , <i>Curcuma longa</i> , <i>Melia toosendan</i> , <i>Bupleurum chinense</i> , <i>Paeonia lactiflora</i> , <i>Corydalis yanhushuo</i> , <i>Citrus aurantium</i> , <i>Atractylodes lancea</i> , <i>Agrimonia pilosa</i> , <i>Glycyrrhiza uralensis</i> | Used for costal pain and jaundice caused by damp-heat in the liver and gallbladder, such as in acute and chronic hepatitis and cholecystitis |
| 25 | Jingzhiwujiapi wines | Traditional Chinese medicine preparations (Volume 13) | <i>Carthamus tinctorius</i> , <i>Curcuma longa</i> , <i>Citrus reticulata</i> , <i>Polygonatum odoratum</i> , <i>Acanthopanax gracilistylus</i> , <i>Chaenomeles speciosa</i> , <i>Achyranthes bidentata</i> , <i>Codonopsis pilosula</i> , <i>Santalum album</i> , <i>Rehmannia glutinosa</i> , etc | Used for hepatic and renal deficiency, muscular and skeletal atrophy, rheumatism and arthralgia muscle and joint contracture, paresthesia of the limbs, lumbar and leg soreness, and epigastric fullness and discomfort |
| 26 | Chenxiangshuyi tablets | Traditional Chinese medicine preparations (Volume 15) | <i>Aquilaria sinensis</i> , <i>Aucklandia lappa</i> , <i>Magnolia officinalis</i> , <i>Amomum villosum</i> , <i>Amomum kravanh</i> , <i>Citrus aurantium</i> , <i>Bupleurum chinense</i> , <i>Corydalis yanhushuo</i> , <i>Cyperus rotundus</i> , <i>Curcuma longa</i> , etc | Used for epigastric fullness and bloating, epigastric pain, vomiting of acid, indigestion, anorexia, and dysphoria |
| 27 | Yuxuebi particles | Traditional Chinese medicine preparations (Volume 16) | <i>Clematis chinensis</i> , <i>Cyatula officinalis</i> , <i>Boswellia carterii</i> , <i>Commiphora myrrha</i> , <i>Carthamus tinctorius</i> , <i>Salvia miltiorrhiza</i> , <i>Ligusticum chuansiong</i> , <i>Angelica sinensis</i> , <i>Curcuma longa</i> , <i>Astragalus membranaceus</i> , <i>Cyperus rotundus</i> | Used for arthralgia due to blood stasis obstructing the collaterals |
| 28 | Shanhuixuanjing tinctures | Traditional Chinese medicine preparations (Volume 18) | <i>Zingiber corallinum</i> , <i>Curcuma longa</i> , <i>Borneolum syntheticum</i> , <i>Salicylic acid</i> , <i>Acetic acid</i> , etc | Used for tinea pedis, tinea manus, and onychomycosis |
| 29 | Wudizhitong liniments | Traditional Chinese medicine preparations (Volume 19) | <i>Aconitum carmichaelii</i> , <i>Aconitum kusnezoffii</i> , <i>Arisaema erubescens</i> , <i>Carthamus tinctorius</i> , <i>Curcuma phaeocaulis</i> , <i>Borneolum syntheticum</i> , <i>Boswellia carterii</i> , <i>Commiphora myrrha</i> , <i>Curcuma longa</i> , <i>Eugenia caryophyllata</i> , <i>Asarum heterotropoides</i> , <i>Paeonia ladiiflora</i> | Used for acute and chronic sprains and contusions, and chilblains |




Fig. 4 Related industries and products of turmeric

proposal of the ISO international standard “ISO 9299: 2024 Traditional Chinese medicine-*Curcuma longa* rhizome”, which applies to the cultivation and commercialization of cultivated turmeric rhizome that is commercially traded and utilized globally as natural medicine, including Chinese materia medica (whole medicinal materials) and processed decoction pieces derived from its rhizome. In addition, based on the turmeric-related research and systematic summary of the fourth national survey of Chinese materia medica resources, we proposed a concept and scientific connotation of generalized science of Chinese material madica, and established a comprehensive framework, the cultivation system of large varieties of Chinese medicinal materials and the application system of the large health industries [145]. Taking turmeric as the subject, turmeric is involved in the three major industries and related products, from primary products to advanced products, including crude drugs (chinese medicinal materials), decoction pieces, foods, dietary supplements, health foods, cosmetics, daily chemical products, innovative drugs, generic drugs, etc. (Fig. 4). Additionally, application of new extraction techniques and delivery systems have brought regulatory challenges. As the products must satisfy rigorous quality control protocols and safety regulations, which often vary significantly across regions, so trans-regional cooperation is needed.

Abbreviations

| | |
|-----|---------------------------------|
| Akt | Protein kinase B |
| ARE | Anti-oxidative response element |
| CAT | Catalase |
| CRP | C-reactive protein |
| DSS | Dextran sulfate sodium |

| | |
|--------|--|
| ERK | Extracellular signal-regulated kinase |
| GPx | Glutathione peroxidase |
| GR | Glutathione reductase |
| GSH | Glutathione |
| GSTA1 | Glutathione S-Transferase Alpha 1 |
| H2O2 | Hydrogen peroxide |
| HBV | Hepatitis B virus |
| HDL-C | High density lipoprotein cholesterol |
| hs-CRP | High-sensitivity-C-reactive protein |
| IKK | Inhibitor of kappa B kinase |
| IL-1β | Interleukin-1β |
| IL-6 | Interleukin-6 |
| IL-8 | Interleukin-8 |
| IR | Insulin resistance |
| IκBa | Nuclear factor kappa-B inhibitor α |
| JAK | Janus kinase |
| JNK | c-Jun N-terminal kinase |
| Keap1 | Kelch-like ECH-associated protein 1 |
| LDL-C | Low-density lipoprotein cholesterol |
| LPS | Lipopolysaccharides |
| MAPKs | Mitogen-activated protein kinases |
| MMP-1 | Matrix metalloproteinases-1 |
| MMP-3 | Matrix metalloproteinases-3 |
| MMP-9 | Matrix metalloproteinases-9 |
| mTOR | Mammalian target of rapamycin |
| NAFLD | Non-alcohol fatty liver disease |
| NASH | Nonalcoholic steatohepatitis |
| NF-κB | Nuclear factor kappa-B |
| NLRP3 | NOD-like receptor protein 3 |
| NO | Nitric oxide |
| Nrf2 | Nuclear factor erythroid 2-related factor 2 |
| PI3K | Phosphatidylinositol 3-kinase |
| PPARγ | Peroxisome proliferator-activated receptor γ |
| ROS | Reactive oxygen species |
| SIRT3 | Sirtuin 3 |
| SOD | Superoxide dismutase |
| STAT | Signal transducers and activators of transcription |
| TG | Triglyceride |
| TLR4 | Toll-like receptor 4 |
| TNF-α | Tumor necrosis factor-α |
| TREM2 | Triggering receptor expressed on myeloid cells 2 |

Acknowledgements

Thanks Qianru Rao, Shangxiao An, and Lulu Weng for their contributions to the chemical structure diagrams and health foods.

Author contributions

Junning Zhao and Hua Hua proposed the framework of this review. Weiwei Tian, Li Liu, and Dongmei Yu drafted the manuscript. Qingmiao Li provided images related to botany. Weiwei Tian, Ping Chen, Junning Zhao and Hua Hua revised the manuscript. Weiwei Tian and Ping Chen improved the language. All authors read and approved the final manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (No. 82274213), Fundamental Research Funds for Sichuan Provincial Scientific Research Institutes (No. 2024JDKY0026), Sichuan Province Traditional Chinese Medicine Technology Industry Innovation Team Special Project (No. 2022C009), Special Project for Scientific and Technological Research of Sichuan Provincial Administration of Traditional Chinese Medicine (No. 2024MS156).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors have read and agreed to the published version of the manuscript.

Competing interests

All authors declared no competing interests.

Received: 6 December 2024 Accepted: 25 April 2025

Published online: 28 May 2025

References

1. Fuloria S, Mehta J, Chandel A, Sekar M, Rani N, Begum MY, et al. A comprehensive review on the therapeutic potential of *Curcuma longa* Linn. in relation to its major active constituent curcumin. *Front Pharmacol*. 2022;13:820806.
2. Bhowmik D, Kumar KPS, Chandira M, Jayakar B. Turmeric: A Herbal and Traditional Medicine. 2008.
3. Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, et al. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. *Front Pharmacol*. 2020;11:01021.
4. Chen J, Yin LL, He JX, Xia Q, Li M, He G. Breeding of a new cultivar "Chuanjianghuang 1" of Sichuan Dao-di herbs *Curcuma Longae* Rhizoma and *Curcuma Radix*. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J Chin Mater Med*. 2020;45:3079–84.
5. Pheap D, Chhim K, Hoeun S, In S. Study on the physicochemical, nutritional, and phytochemical properties in five turmeric varieties. *IOP Conf Ser: Earth Environ Sci*. 2024. <https://doi.org/10.1088/1755-1315/1297/1/012009>.
6. Alam MA, Roy S, Rahman MA, Islam MR, Rahman MM, Obaidullah AJ, et al. Study on the genetic variability and adaptability of turmeric (*Curcuma longa* L.) genotypes for development of desirable cultivars. *PLoS ONE*. 2024;19:e0297202.
7. Yin Y, Xie X, Zhou L, Yin X, Guo S, Zhou X, et al. A chromosome-scale genome assembly of turmeric provides insights into curcumin biosynthesis and tuber formation mechanism. *Front Plant Sci*. 2022;13:1003835.
8. Singh V, Dhivya S. An economic analysis of turmeric marketing in Erode district of Tamil Nadu. *J Hill Agric*. 2017. <https://doi.org/10.5958/2230-7338.2017.00068.4>.
9. Gururani S, Gairola K, Kumar R, Prakash O, Dubey SK. Altitudinal and geographical variations in phytochemical composition and biological activities of *Curcuma longa* accession from Uttarakhand, the Himalayan region. *J Food Process Preserv*. 2022;46:e16384.
10. Hua H, Tian WW, Ma JY, Wang YF, Wang YQ, Yan ZX, et al. Bioinformatics database and production layout visual analysis platform of medicinal plants: a case study of Dao-di medicinal materials in Sichuan province. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J Chin Mater Med*. 2024;49:1989–95.
11. Niranjana A, Prakash D. Chemical constituents and biological activities of turmeric (*Curcuma longa* L.) -a review. *J Food Sci Technol*. 2008;45:109–16.
12. Liu S, Liu J, He L, Liu L, Cheng B, Zhou F, et al. A comprehensive review on the benefits and problems of curcumin with respect to human health. *Molecules*. 2022. <https://doi.org/10.3390/molecules27144400>.
13. El-Saadony MT, Yang T, Korma SA, Sitohy M, Abd El-Mageed TA, Selim S, et al. Impacts of turmeric and its principal bioactive curcumin on human health: pharmaceutical, medicinal, and food applications: a comprehensive review. *Front Nutr*. 2022;9:1040259.
14. Nair KP. Nutraceutical properties of turmeric. Cham: Springer; 2019.
15. Nc S. Curcuma Longa (Turmeric): A Condiment of Great Therapeutic Value Tested with the Ayurveda up to the Modern Medicine. 2021.
16. Su XL, Wang JW, Che H, Wang CF, Jiang H, Lei X, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. *Chin Med J*. 2020;133:2987–97.
17. Verma RK, Kumari P, Maurya RK, Kumar V, Verma RB, Singh RK. Medicinal properties of turmeric (*Curcuma longa* L.): a review. Delhi: AkiNik Publications; 2018.
18. Thomas-Eapen NE. Turmeric: the intriguing yellow spice with medicinal properties. *Explore*. 2009;5:114–5.
19. Kim JH, Yang HJ, Kim Y-J, Park S, Lee O-H, Kim KS, et al. Korean turmeric is effective for dyslipidemia in human intervention study. *J Ethnic Foods*. 2016;3:213–21.
20. Olife I, Chidiogo OA, Peter AM. Status assessment of spice resources in Nigeria. *J Biol Agric Healthcare*. 2013;3(9):12–9.
21. Ayati Z, Ramezani M, Amiri MS, Moghadam AT, Rahimi H, Abdollahzade A, et al. Ethnobotany, phytochemistry and traditional uses of *Curcuma* spp. and pharmacological profile of two important species (*C. longa* and *C. zedoaria*): a review. *Curr Pharma Design*. 2019;25:871–935.
22. Ahmed HM. Ethnopharmacobotanical study on the medicinal plants used by herbalists in Sulaymaniyah Province, Kurdistan, Iraq. *J Ethnobiol Ethnomed*. 2016;12:8.
23. Albaqami JJ, Hamdi H, Narayanankutty A, Visakh NU, Sasidharan A, Kutithodi AM, et al. Chemical composition and biological activities of the leaf essential oils of *Curcuma longa*, *Curcuma aromatica* and *Curcuma angustifolia*. *Antibiotics*. 2022. <https://doi.org/10.3390/antibiotics11111547>.
24. Wang W, Liu D, Zhang X, Chen D, Cheng Y, Shen F. Plant MicroRNAs in cross-kingdom regulation of gene expression. *Int J Mol Sci*. 2018. <https://doi.org/10.3390/ijms19072007>.
25. Dai Q, Zhou D, Xu L, Song X. Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats. *Drug Des Dev Ther*. 2018;12:4095–105.
26. Ran Z, Zhang Y, Wen X, Ma J. Curcumin inhibits high glucose-induced inflammatory injury in human retinal pigment epithelial cells through the ROS-PI3K/AKT/mTOR signaling pathway. *Mol Med Rep*. 2019;19:1024–31.
27. Zhang Y, Zeng Y. Curcumin reduces inflammation in knee osteoarthritis rats through blocking TLR4/MyD88/NF- κ B signal pathway. *Drug Dev Res*. 2019;80:353–9.
28. Wang L, Zheng W, Men Q, Ren X, Song S, Ai C. Curcumin-loaded polysaccharide microparticles alleviated DSS-induced ulcerative colitis by improving intestinal microecology and regulating MAPK/NF- κ B/Nrf2/NLRP3 pathways. *Int J Biol Macromol*. 2024;281:136687.
29. Ibáñez MD, Blázquez MA. *Curcuma longa* L. rhizome essential oil from extraction to its agri-food applications. A review. *Plants*. 2020. <https://doi.org/10.3390/plants10010044>.
30. Del Prete D, Millán E, Pollastro F, Chianese G, Luciano P, Collado JA, et al. Turmeric sesquiterpenoids: expeditious resolution, comparative bioactivity, and a new bicyclic turmeronoid. *J Nat Prod*. 2016;79:267–73.

31. Saji R, Uchio R, Fuwa A, Okuda-Hanafusa C, Kawasaki K, Muroyama K, et al. Turmeronols (A and B) from *Curcuma longa* have anti-inflammatory effects in lipopolysaccharide-stimulated BV-2 microglial cells by reducing NF- κ B signaling. *Biosci Microbio*, Food Health. 2023;42:172–9.
32. Yuan T, Zhang C, Qiu C, Xia G, Wang F, Lin B, et al. Chemical constituents from *Curcuma longa* L. and their inhibitory effects of nitric oxide production. *Natl Product Res*. 2017;32:1887–92.
33. Brockmueller A, Buhrmann C, Shayan P, Shakibaei M. Catechin A modulates inflammatory and autophagy signals for the prevention and treatment of osteoarthritis. *Front Immunol*. 2024;15:1363947.
34. Singh U, Barik A, Singh BG, Priyadarsini KI. Reactions of reactive oxygen species (ROS) with curcumin analogues: structure-activity relationship. *Free Radical Res*. 2011;45:317–25.
35. Dehghani Z, Meratan AA, Saboury AA, Nemat-Gorgani M. α -Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: protection by curcumin, and possible role in pathogenesis of Parkinson's disease. *Biochim Biophys Acta (BBA) - Biomembranes*. 2020. <https://doi.org/10.1016/j.bbame.2020.183251>.
36. Lee H-Y, Kim S-W, Lee G-H, Choi M-K, Chung H-W, Lee Y-C, et al. Curcumin and *Curcuma longa* L. extract ameliorate lipid accumulation through the regulation of the endoplasmic reticulum redox and ER stress. *Sci Re*. 2017. <https://doi.org/10.1038/s41598-017-06872-y>.
37. Guo SP, Chang HC, Lu LS, Liu DZ, Wang TJ. Activation of kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2/antioxidant response element pathway by curcumin enhances the anti-oxidative capacity of corneal endothelial cells. *Biomed Pharmacother*. 2021;141:111834.
38. Russo M, Giacomo AD, Fiore F, Spagnuolo C, Carbone V, Minasi P, et al. Curcumin prevents cadmium or H₂O₂-induced oxidative stress via Nrf2/ARE signaling and autophagy in myeloid cells. *Curr Res Biotechnol*. 2024. <https://doi.org/10.1016/j.crbiot.2024.100266>.
39. Altamimi JZ, AlFaris NA, Al-Farga AM, Alshammari GM, BinMowyna MN, Yahya MA. Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKC β /p66Shc axis and activation of FOXO-3a. *J Nutr Biochem*. 2021. <https://doi.org/10.1016/j.jnutb.2020.108515>.
40. Zhang T, Chen X, Qu Y, Ding Y. Curcumin alleviates oxygen-glucose-deprivation/reperfusion-induced oxidative damage by regulating miR-1287-5p/LONP2 Axis in SH-SY5Y Cells. *Anal Cell Pathol*. 2021;2021:5548706.
41. Ishaq A, Gulzar H, Hassan A, Kamran M, Riaz M, Parveen A, et al. Ameliorative mechanisms of turmeric-extracted curcumin on arsenic (As)-induced biochemical alterations, oxidative damage, and impaired organ functions in rats. *Environ Sci Pollut Res Int*. 2021;28:66313–26.
42. Wu H, Liu Z, Zhang Y, Gao B, Li Y, He X, et al. Chemical composition of turmeric (*Curcuma longa* L.) ethanol extract and its antimicrobial activities and free radical scavenging capacities. 2024. <https://doi.org/10.3390/foods13101550>.
43. Avanzo GB, Ferreira FD, Bomfim NS, de Santos PASR, Peralta RM, Brugnari T, et al. *Curcuma longa* L. essential oil composition, antioxidant effect, and effect on fusarium verticillioides and fumonisin production. *Food Control*. 2017;73:806–13.
44. Zhang B, Yang J, Li X, Zhu H, Sun J, Jiang L, et al. Tetrahydrocurcumin ameliorates postinfarction cardiac dysfunction and remodeling by inhibiting oxidative stress and preserving mitochondrial function via SIRT3 signaling pathway. *Phytomed: Int J Phytother Phytopharmacol*. 2023;121:155127.
45. Wang Q, Zhong Y, Li N, Du L, Ye R, Xie Y, et al. Combination of dimethylmethoxy chromanol and turmeric root extract synergistically attenuates ultraviolet-induced oxidative damage by increasing endogenous antioxidants in HaCaT cells. *Skin Res Technol*. 2023;29:e13539.
46. Xu Y, Lu J, Li M, Wang T, Wang K, Cao Q, et al. Diabetes in China part 1: epidemiology and risk factors. *Lancet Public Health*. 2024;9:e1089–97.
47. Marton LT, Pescinini ESLM, Camargo MEC, Barbalho SM, Haber J, Sinatorta RV, et al. The effects of curcumin on diabetes mellitus: a systematic review. *Front Endocrinol*. 2021;12:669448.
48. Islam MZ, Akter J, Hossain MA, Islam MS, Islam P, Goswami C, et al. Anti-inflammatory, wound healing, and anti-diabetic effects of pure active compounds present in the ryudai gold variety of *Curcuma longa*. *Molecules*. 2024. <https://doi.org/10.3390/molecules29122795>.
49. Zhong Y, Xiao Y, Gao J, Zheng Z, Zhang Z, Yao L, et al. Curcumin improves insulin sensitivity in high-fat diet-fed mice through gut microbiota. *Nutr Metab*. 2022;19:76.
50. Lee SJ, Chandrasekran P, Mazucanti CH, O'Connell JF, Egan JM, Kim Y. Dietary curcumin restores insulin homeostasis in diet-induced obese aged mice. *Aging*. 2022;14:225–39.
51. Wu L-Y, Chen C-W, Chen L-K, Chou H-Y, Chang C-L, Juan C-C. Curcumin attenuates adipogenesis by inducing preadipocyte apoptosis and inhibiting adipocyte differentiation. *Nutrients*. 2019. <https://doi.org/10.3390/nu11102307>.
52. <2021-AEMB.pdf>.
53. Sahebkar A, Sathyapalan T. Correction to: natural products and human diseases. *Cham: Springer*; 2022.
54. Song Z, Revelo X, Shao W, Tian L, Zeng K, Lei H, et al. Dietary curcumin intervention targets mouse white adipose tissue inflammation and brown adipose tissue UCP1 expression. *Obesity*. 2018;26:547–58.
55. Jin HAI, Qiao FAN, Wang YAN, Xu Y, Shang YAN. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway. *Oncol Rep*. 2015;34:2782–9.
56. Li Z, Gao Y, Li L, Xie S. Curcumin inhibits papillary thyroid cancer cell proliferation by regulating lncRNA LINC00691. *Anal Cell Pathol*. 2022;2022:5946670.
57. Liu C, Rokavec M, Huang Z, Hermeking H. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. *Cell Death Differ*. 2023;30:1771–85.
58. Li M, Guo T, Lin J, Huang X, Ke Q, Wu Y, et al. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via hedgehog/gli1 signaling pathway. *J Ethnopharmacol*. 2022;283:114689.
59. Jin G, Yang Y, Liu K, Zhao J, Chen X, Liu H, et al. Combination curcumin and (-)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway. *Oncogenesis*. 2017;6:e384.
60. Zhang Y, Xiang J, Zhu N, Ge H, Sheng X, Deng S, et al. Curcumin in combination with omacetaxine suppress lymphoma cell growth, migration, invasion, and angiogenesis via inhibition of VEGF/Akt signaling pathway. *Front Oncol*. 2021;11:656045.
61. Wang Y, Li J, Guo J, Wang Q, Zhu S, Gao S, et al. Cytotoxic and antitumor effects of curzerene from *Curcuma longa*. *Planta Med*. 2017;83:23–9.
62. Tang J, Peng H, Xu F, Luo P, Liu D, Chen L. Demethoxycurcumin represses cervical cancer growth through PPAR γ -regulated proliferation and apoptosis. *Acta Biochim Biophys Sin*. 2023;55:1331–3.
63. Shi L, Sun G, Zhu H. Demethoxycurcumin analogue DMC-BH inhibits orthotopic growth of glioma stem cells by targeting JNK/ERK signaling. *Aging*. 2020;12:14718–35.
64. Feng Q, Zhang X, Zhao X, Liu J, Wang Q, Yao Y, et al. Intranasal delivery of pure nanodrug loaded liposomes for Alzheimer's disease treatment by efficiently regulating microglial polarization. *Small*. 2024;20:e2405781.
65. Yuliani S, Partadiredja G. The neuroprotective effects of an ethanolic turmeric (*Curcuma longa* L.) extract against trimethyltin-induced oxidative stress in rats. *Nutr Neurosci*. 2019;22:797–804.
66. He HJ, Xiong X, Zhou S, Zhang XR, Zhao X, Chen L, et al. Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson's models. *Neurochem Int*. 2022;155:105297.
67. Lee H, Liu Z, Dong L, Lee DY, Yoon D, Oh H, et al. Anti-neuroinflammatory and neuroprotective effect of intermedin B isolated from the *Curcuma longa* L via NF- κ B and ROS inhibition in BV2 microglia and HT22 hippocampal cells. *Int J Mol Sci*. 2023. <https://doi.org/10.3390/ijms24087390>.
68. Zhai SS, Ruan D, Zhu YW, Li MC, Ye H, Wang WC, et al. Protective effect of curcumin on ochratoxin A-induced liver oxidative injury in duck is mediated by modulating lipid metabolism and the intestinal microbiota. *Poult Sci*. 2020;99:1124–34.
69. Cunningham RP, Moore MP, Moore AN, Healy JC, Roberts MD, Rector RS, et al. Curcumin supplementation mitigates NASH development and progression in female Wistar rats. *Physiol Rep*. 2018;6:e13789.
70. Hong T, Jiang X, Zou J, Yang J, Zhang H, Mai H, et al. Hepatoprotective effect of curcumin against bisphenol A-induced hepatic steatosis via modulating gut microbiota dysbiosis and related gut-liver axis activation in CD-1 mice. *J Nutr Biochem*. 2022;109:109103.

71. Hussain S, Ashafaq M, Alshahrani S, Bokar IAM, Siddiqui R, Alam MI, et al. Hepatoprotective effect of curcumin nano-lipid carrier against cypermethrin toxicity by countering the oxidative, inflammatory, and apoptotic changes in wistar rats. *Molecules*. 2023. <https://doi.org/10.3390/molecules28020881>.
72. Sandhiutami NMD, Dewi RS, Khairani S, Putri RNA. Enhancement of curcumin level and hepatoprotective effect in rats through antioxidant activity following modification into nanosized particles. *Vet World*. 2022;15:2323–32.
73. Sasidharan NK, Sreekala SR, Jacob J, Nambisan B. In vitro synergistic effect of curcumin in combination with third generation cephalosporins against bacteria associated with infectious diarrhea. *Biomed Res Int*. 2014;2014:561456.
74. Kim MK, Choi GJ, Lee HS. Fungicidal property of *Curcuma longa* L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. *J Agric Food Chem*. 2003;51:1578–81.
75. Vetricka V, Vetrickova J, Fernandez-Botran R. Effects of curcumin on helicobacter pylori infection. *Ann Transl Med*. 2016;4:479.
76. de Lobo SFD, Butkevych E, Natrilarasu PK, Fromm A, Mousavi S, Moos V, et al. Curcumin mitigates immune-induced epithelial barrier dysfunction by *Campylobacter jejuni*. *Int J Mol Sci*. 2019. <https://doi.org/10.3390/ijms20194830>.
77. Martins CV, da Silva DL, Neres AT, Magalhães TF, Watanabe GA, Modolo LV, et al. Curcumin as a promising antifungal of clinical interest. *J Antimicrob Chemother*. 2009;63:337–9.
78. Li Y, Wang J, Liu Y, Luo X, Lei W, Xie L. Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro. *J Gen Virol*. 2020;101:1079–84.
79. Kim HJ, Yoo HS, Kim JC, Park CS, Choi MS, Kim M, et al. Antiviral effect of *Curcuma longa* Linn extract against hepatitis B virus replication. *J Ethnopharmacol*. 2009;124:189–96.
80. Dao TT, Nguyen PH, Won HK, Kim EH, Park J, Won BY, et al. Curcuminoids from *Curcuma longa* and their inhibitory activities on influenza A neuraminidases. *Food Chem*. 2012;134:21–8.
81. Kiuchi F, Goto Y, Sugimoto N, Akao N, Kondo K, Tsuda Y. Nematocidal activity of turmeric: synergistic action of curcuminoids. *Chem Pharm Bull*. 1993;41:1640–3.
82. Roth GN, Chandra A, Nair MG. Novel bioactivities of *Curcuma longa* constituents. *J Nat Prod*. 1998;61:542–5.
83. Bamba Y, Yun YS, Kunugi A, Inoue H. Compounds isolated from *Curcuma aromatica* Salisb. inhibit human P450 enzymes. *J Nat Med*. 2011;65:583–7.
84. Lekshmi PC, Arimboor R, Indulekha PS, Menon AN. Turmeric (*Curcuma longa* L.) volatile oil inhibits key enzymes linked to type 2 diabetes. *Int J Food Sci Nutr*. 2012;63:832–4.
85. Ouyang M, Luo Z, Zhang W, Zhu D, Lu Y, Wu J, et al. Protective effect of curcumin against irinotecan-induced intestinal mucosal injury via attenuation of NF- κ B activation, oxidative stress and endoplasmic reticulum stress. *Int J Oncol*. 2019;54:1376–86.
86. Rahman MM, Noman MAA, Hossain MW, Alam R, Akter S, Kabir MM, et al. *Curcuma longa* L. prevents the loss of β -tubulin in the brain and maintains healthy aging in drosophila melanogaster. *Mol Neurobiol*. 2022;59:1819–35.
87. Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S. The effect of curcumin on reducing atherogenic risks in obese patients with type 2 diabetes: a randomized controlled trial. *Nutrients*. 2024. <https://doi.org/10.3390/nu16152441>.
88. Neta JFF, Veras VS, Sousa DF, Cunha M, Queiroz MVO, Neto J, et al. Effectiveness of the piperine-supplemented *Curcuma longa* L. in metabolic control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical trial. *Int J Food Sci Nutr*. 2021;72:968–77.
89. Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. *Complement Ther Med*. 2017;33:1–5.
90. Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S. Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial. *Nutr J*. 2024;23:119.
91. Srinivasan A, Selvarajan S, Kamalanathan S, Kadiravan T, Prasanna Lakshmi NC, Adithan S. Effect of *Curcuma longa* on vascular function in native Tamilians with type 2 diabetes mellitus: a randomized, double-blind, parallel arm, placebo-controlled trial. *Phytother Res: PTR*. 2019;33:1898–911.
92. Asadi S, Gholami MS, Siassi F, Qorbani M, Khamoshian K, Sotoudeh G. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled clinical trial. *Complement Ther Med*. 2019;43:253–60.
93. Navekar R, Raftar M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M. Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. *J Am Coll Nutr*. 2017;36:261–7.
94. Ghaffari A, Raftar M, Navekar R, Sepehri B, Asghari-Jafarabadi M, Ghavami SM. Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD). *Int J Vitam Nutr Res*. 2019;89:293–302.
95. Bateni Z, Rahimi HR, Hedayati M, Afsharian S, Goudarzi R, Sohrab G. The effects of nano-curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: a randomized, double-blind clinical trial. *Phytother Res: PTR*. 2021;35:3945–53.
96. Majeed M, Nagabhushanam K, Devarajan TV, Saklecha S, Reddy SVK, Mundkur L. A minor metabolite from *Curcuma longa* effective against metabolic syndrome: results from a randomized, double-blind, placebo-controlled clinical study. *Food Funct*. 2023;14:4722–33.
97. Singhal S, Hasan N, Nirmal K, Chawla R, Chawla S, Kalra BS, et al. Bio-available turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol. *Trials*. 2021;22:105.
98. Atabaki M, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. Significant immunomodulatory properties of curcumin in patients with osteoarthritis: a successful clinical trial in Iran. *Int Immunopharmacol*. 2020;85:106607.
99. Lopresti AL, Smith SJ, Jackson-Michel S, Fairchild T. An investigation into the effects of a curcumin extract (curcugen[®]) on osteoarthritis pain of the knee: a randomised, double-blind, placebo-controlled study. *Nutrients*. 2021. <https://doi.org/10.3390/nu14010041>.
100. Alvarenga L, Salaroli R, Cardozo L, Santos RS, de Brito JS, Kemp JA, et al. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: a pilot randomized, double-blind, controlled study. *Clin Nutr*. 2020;39:3594–600.
101. Soni TP, Gupta AK, Sharma LM, Singhal H, Sharma S, Gothwal RS. A randomized, placebo-controlled study to evaluate the effect of bio-enhanced turmeric formulation on radiation-induced oral mucositis. *ORL; J Oto-Rhino-Laryngol Related Specialt*. 2022;84:103–13.
102. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. *Phytother res: PTR*. 2014;28:1461–7.
103. Thomas PL, Kang HK, Rishi KS. Randomized control study of the effects of turmeric mouthwash on oral health status, treatment-induced mucositis, and associated oral dysfunctions among patients with head and neck cancer. *Cancer Nurs*. 2023;46:36–44.
104. Heidari-Beni M, Moravejolahkami AR, Gorgian P, Askari G, Tarrahi MJ, Bahreini-Esfahani N. Herbal formulation “turmeric extract, black pepper, and ginger” versus naproxen for chronic knee osteoarthritis: a randomized, double-blind, controlled clinical trial. *Phytother Res: PTR*. 2020;34:2067–73.
105. Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Boqué N, Puiggròs F, et al. Acute effects of turmeric extracts on knee joint pain: a pilot randomized controlled trial. *J Med Food*. 2021;24:436–40.
106. Freitas ES-SNC, Rodrigues HCN, Pereira Martins TF, Braga CC, Silva MAC, da Carlos Cunha L, et al. Turmeric supplementation with piperine is more effective than turmeric alone in attenuating oxidative stress and inflammation in hemodialysis patients: a randomized, double-blind clinical trial. *Free Radical Biol Med*. 2022;193:648–55.
107. Jalalmanesh S, Mansouri P, Rajabi M, Monji F. Therapeutic effects of turmeric topical cream in vitiligo: a randomized, double-blind, placebo-controlled pilot study. *J Cosmet Dermatol*. 2022;21:4454–61.
108. Bahraini P, Rajabi M, Mansouri P, Sarafian G, Chalangari R, Azizian Z. Turmeric tonic as a treatment in scalp psoriasis: a randomized placebo-control clinical trial. *J Cosmet Dermatol*. 2018;17:461–6.

109. Bahrami A, Zarban A, Rezapour H, Agha Amini Fashami A, Ferns GA. Effects of curcumin on menstrual pattern, premenstrual syndrome, and dysmenorrhea: a triple-blind, placebo-controlled clinical trial. *Phytother Res*. 2021;35:6954–62.
110. Bohra A, Maheswari TNU, Harsh A, Garg A. Black turmeric and aloe vera in the management of oral submucous fibrosis: a prospective clinical study. *Asian Pac J Cancer Prevent: APJCP*. 2021;22:3941–7.
111. Henrotin Y, Malaise M, Wittoek R, de Vlam K, Brasseur JP, Luyten FP, et al. Bio-optimized *Curcuma longa* extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study. *Arthritis Res Ther*. 2019;21:179.
112. Pakfetrat M, Akmal M, Malekmakan L, Dabaghimanesh M, Khorsand M. Role of turmeric in oxidative modulation in end-stage renal disease patients. *Hemodial Int*. 2015;19:124–31.
113. Lopresti AL, Smith SJ, Rea A, Michel S. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study. *BMC Complement Med Ther*. 2021;21:40.
114. Adab Z, Eghtesadi S, Vafa MR, Heydari I, Shojaii A, Haqqani H, et al. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. *Phytother Res: PTR*. 2019;33:1173–81.
115. Hesami S, Kavianpour M, Rashidi Nooshabadi M, Yousefi M, Lalooha F, Khadem HH. Randomized, double-blind, placebo-controlled clinical trial studying the effects of turmeric in combination with mefenamic acid in patients with primary dysmenorrhoea. *J gynecol Obstet Human Reprod*. 2021;50:101840.
116. Pakfetrat M, Basiri F, Malekmakan L, Roozbeh J. Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. *J Nephrol*. 2014;27:203–7.
117. Reis D, Alvarenga L, Cardozo L, Baptista BG, Fanton S, Paiva BR, et al. Can curcumin supplementation break the vicious cycle of inflammation, oxidative stress, and uremia in patients undergoing peritoneal dialysis? *Clin Nutr ESPEN*. 2024;59:96–106.
118. Rao S, Dinkar C, Vaishnav LK, Rao P, Rai MP, Fayad R, et al. The Indian spice turmeric delays and mitigates radiation-induced oral mucositis in patients undergoing treatment for head and neck cancer: an investigation study. *Integr Cancer Ther*. 2014;13:201–10.
119. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor- β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. *Scand J Urol Nephrol*. 2011;45:365–70.
120. Kim SW, Ha KC, Choi EK, Jung SY, Kim MG, Kwon DY, et al. The effectiveness of fermented turmeric powder in subjects with elevated alanine transaminase levels: a randomised controlled study. *BMC Complement Altern Med*. 2013;13:58.
121. Amin F, Islam N, Anila N, Gilani AH. Clinical efficacy of the co-administration of turmeric and black seeds (Kalongi) in metabolic syndrome—a double blind randomized controlled trial—TAK-MetS trial. *Complement Ther Med*. 2015;23:165–74.
122. Khiljee S, Rehman N, Khiljee T, Loebenberg R, Ahmad RS. Formulation and clinical evaluation of topical dosage forms of Indian Penny Wort, walnut and turmeric in eczema. *Pak J Pharm Sci*. 2015;28:2001–7.
123. Ahmadi S, Mehrabi Z, Zare M, Ghadir S, Masoumi SJ. Efficacy of nanocurcumin as an add-on treatment for patients hospitalized with COVID-19: a double-blind, randomized clinical trial. *Int J Clin Pract*. 2023;2023:5734675.
124. Samadian F, Dalili N, Poor-Reza Gholi F, Fattah M, Malih N, Nafar M, et al. Evaluation of curcumin's effect on inflammation in hemodialysis patients. *Clin Nutr ESPEN*. 2017;22:19–23.
125. Panahi Y, Khalili N, Sahebi E, Namazi S, Atkin SL, Majeed M, et al. Curcuminoids plus piperine modulate adipokines in type 2 diabetes mellitus. *Curr Clin Pharmacol*. 2017;12:253–8.
126. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. *J Diet Suppl*. 2016;13:209–20.
127. Alidadi M, Sahebkar A, Eslami S, Vakilian F, Jarahi L, Alinezhad-Namaghi M, et al. The effect of curcumin supplementation on pulse wave velocity in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. *Adv Exp Med Biol*. 2021;1308:1–11.
128. Varma K, Amalraj A, Divya C, Gopi S. The efficacy of the novel bioavailable curcumin (cureit) in the management of sarcopenia in healthy elderly subjects: a randomized, placebo-controlled, double-blind clinical study. *J Med Food*. 2021;24:40–9.
129. Phoolcharoen N, Oranratanaphan S, Ariyasriwatana C, Worasethsin P. Efficacy of curcuminoids for reducing postoperative pain after laparoscopic gynecologic surgery: a pilot randomized trial. *J Complement Integr Med*. 2019. <https://doi.org/10.1515/jcim-2018-0224>.
130. Nouri-Vaskeh M, Malek Mahdavi A, Afshan H, Alizadeh L, Zarei M. Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: a randomized controlled trial. *Phytother Res: PTR*. 2020;34:1446–54.
131. Mirhafez SR, Azimi-Nezhad M, Dehabeh M, Hariri M, Naderan RD, Movahedi A, et al. The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial. *Adv Exp Med Biol*. 2021;1308:25–35.
132. Heshmati J, Golab F, Morvaridzadeh M, Potter E, Akbari-Fakhrabadi M, Farsi F, et al. The effects of curcumin supplementation on oxidative stress, sirtuin-1 and peroxisome proliferator activated receptor γ coactivator 1 α gene expression in polycystic ovarian syndrome (PCOS) patients: a randomized placebo-controlled clinical trial. *Diabetes Metab Syndr*. 2020;14:77–82.
133. Nouri-Vaskeh M, Afshan H, Malek Mahdavi A, Alizadeh L, Fan X, Zarei M. Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: a randomized, double-blind placebo-controlled trial. *Complement Ther Med*. 2020;49:102351.
134. Shep D, Khanwelkar C, Gade P, Karad S. Efficacy and safety of combination of curcuminoid complex and diclofenac versus diclofenac in knee osteoarthritis: a randomized trial. *Medicine*. 2020;99:e19723.
135. Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, Salehizadeh L, Rahmani S, Behnam B, et al. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: a randomized controlled trial. *Complement Ther Med*. 2020;49:102322.
136. Uchio R, Muroyama K, Okuda-Hanafusa C, Kawasaki K, Yamamoto Y, Murosaki S. Hot water extract of *Curcuma longa* L. improves serum inflammatory markers and general health in subjects with overweight or prehypertension/mild hypertension: a randomized, double-blind, placebo-controlled trial. *Nutrients*. 2019. <https://doi.org/10.3390/nu11081822>.
137. Adibian M, Hodaei H, Nikpayam O, Sohrab G, Hekmatdoost A, Hedayati M. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Phytother Res: PTR*. 2019;33:1374–83.
138. Mohammadi E, Tamaddon A, Quej D, Nasser E, Zayeri F, Zand H, et al. An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β -thalassemia major patients: a double-blind randomized controlled clinical trial. *Phytother Res: PTR*. 2018;32:1828–35.
139. Morgia G, Russo GI, Urzi D, Privitera S, Castelli T, Favilla V, et al. A phase II, randomized, single-blinded, placebo-controlled clinical trial on the efficacy of curcumin and calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. *Archivio italiano di urologia, andrologia*. 2017;89:110–3.
140. Srivastava S, Saksena AK, Khattri S, Kumar S, Dagur RS. Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of knee: a four-month, double-blind, randomized, placebo-controlled trial. *Inflammopharmacology*. 2016;24:377–88.
141. Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. *J diet suppl*. 2016;13:93–105.
142. Gopinath H, Karthikeyan K. Turmeric: a condiment, cosmetic and cure. *Indian J Dermatol Venereol Leprol*. 2018;84:16–21.
143. Kim DW, Choi CH, Park JP, Lee SJ. Nanospheres loaded with curcumin improve the bioactivity of umbilical cord blood-mesenchymal stem cells via c-src activation during the skin wound healing process. *Cells*. 2020. <https://doi.org/10.3390/cells9061467>.

144. Kim K, Jeon HM, Choi KC, Sung GY. Testing the effectiveness of curcuma longa leaf extract on a skin equivalent using a pumpless skin-on-a-chip model. *Int J Mol Sci*. 2020. <https://doi.org/10.3390/ijms21113898>.
145. Zhao JN, Hua H, Yang AD, Zhang YG, Dai Y, Li QM, et al. Generalized science of Chinese material medica-from preventive treatment of disease to Chinese medicine health industry. *Zhongguo Zhong yao za zhi* = *Zhongguo zhongyao zazhi* = *China J Chin Mater Med*. 2018;43:4177–81.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.